<SEC-DOCUMENT>0001193125-22-235248.txt : 20220831
<SEC-HEADER>0001193125-22-235248.hdr.sgml : 20220831
<ACCEPTANCE-DATETIME>20220831164314
ACCESSION NUMBER:		0001193125-22-235248
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20220831
DATE AS OF CHANGE:		20220831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266841
		FILM NUMBER:		221218437

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>d309570ds3a.htm
<DESCRIPTION>S-3/A
<TEXT>
<HTML><HEAD>
<TITLE>S-3/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August 31, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-266841</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>Amendment&nbsp;No.&nbsp;1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-1475642</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices and
principal place of business) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kevin S. Boyle, Sr. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address and telephone number of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Melinda Lackey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Senior Vice President, Legal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston,
TX 77054</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT STYLE="white-space:nowrap">355-4099</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Brian K. Rosenzweig</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lilit Kazangyan</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Covington&nbsp;&amp; Burling LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>620 Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York,
NY 10018</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">841-1000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of proposed sale to the public: </B>From time to time after the effective date of this registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the
following&nbsp;box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant
to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following&nbsp;box:&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this
form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This registration statement contains two prospectuses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus which covers the offering, issuance and sale by the registrant of up to a maximum aggregate
offering price of $200,000,000 of the registrant&#146;s common stock, preferred stock, debt securities, and/or warrants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an equity distribution agreement prospectus covering the offering, issuance and sale by the registrant of up to a
maximum aggregate offering price of $50,000,000 of the registrant&#146;s common stock that may be issued and sold under an equity distribution agreement with Piper Sandler&nbsp;&amp; Co., or Piper Sandler. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any other securities to be offered pursuant to the base prospectus will
be specified in one or more prospectus supplements to the base prospectus. The equity distribution agreement prospectus immediately follows the base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $50,000,000 of shares of common stock that may be offered, issued and sold under the equity distribution agreement prospectus is included in the
$200,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the equity distribution agreement, any portion of the $50,000,000 included in the equity distribution agreement
prospectus that is not sold pursuant to the equity distribution agreement will be available for sale in other offerings pursuant to the base prospectus and an accompanying prospectus supplement, and if no shares are sold under the equity
distribution agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and an accompanying prospectus supplement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B>Subject to completion, dated August 31, 2022 </B></FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309570g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may offer
and sell up to $200,000,000 in the aggregate of the securities identified above, either individually or in combination, at prices and on terms described in one or more supplements to this prospectus. We may also offer securities as may be issuable
upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. Each time we offer and sell
securities, we will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The
prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market
under the symbol &#147;TCRT.&#148; On August 29, 2022, the closing price of our common stock, as reported on the Nasdaq Global Select Market, was $2.47. The applicable prospectus supplement will contain information, where applicable, as to other
listings, if any, on the Nasdaq Global Select Market or other securities exchange of the securities covered by the prospectus supplement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities
may be sold to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the section titled &#147;<I>Plan of
Distribution</I>&#148; in this prospectus and in the applicable prospectus supplement. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any
applicable discounts or commissions and options to purchase additional securities will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set
forth in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties
described under the heading &#147;</B><B><I><A HREF="#toc309570_4">Risk Factors</A></I></B><B>&#148; on page 4 of this prospectus and any similar section contained in the applicable prospectus supplement and in any free writing prospectuses we have
authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this
prospectus is truthful or complete. A representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_1">ABOUT THIS PROSPECTUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_2">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_10">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_11">CERTAIN PROVISIONS OF DELAWARE LAW, THE CERTIFICATE OF INCORPORATION AND BYLAWS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_12">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_15">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_16">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc309570_17">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or SEC, using a &#147;shelf&#148; registration process under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we may sell common stock, preferred stock, various series of debt
securities, or warrants to purchase any of such securities, either individually or in combination with other securities described in this prospectus, in one or more offerings from time to time up to an aggregate dollar amount of $200,000,000. This
prospectus provides you with a general description of the securities we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we sell any type or series of securities under this
prospectus, we will provide a prospectus supplement that will include more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information
relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have
incorporated by reference into this prospectus. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus
supplement, will include all material information relating to the applicable offering. Before buying any of the securities being offered, we urge you to carefully read this prospectus, the applicable prospectus supplement and any related free
writing prospectuses we have authorized for use in connection with a specific offering, together with the additional information incorporated herein by reference as described under the heading &#147;<I>Incorporation of Information by
Reference</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus and the applicable prospectus supplement, along with
the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. We take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement and any related free writing prospectus is accurate only as of the
date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, the prospectus supplement or
any related free writing prospectus, or the time of any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus includes summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you may obtain copies of those documents as described under the heading &#147;<I>Where You Can Find More Information</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to &#147;Alaunos,&#148; or the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our&#148; and similar terms refer to Alaunos Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, any applicable prospectus supplement, and the information incorporated by reference herein and therein, contains estimates, projections and
other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is
inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data
from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. Although we believe these sources are reliable, we do not guarantee the accuracy or
completeness of this information and we have not independently verified this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of
data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus, and does not contain
all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in
our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into
this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company
Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered
<FONT STYLE="white-space:nowrap">T-cell</FONT> therapies, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our novel
cancer mutation hotspot TCR library and our proprietary, <FONT STYLE="white-space:nowrap">non-viral</FONT> <I>Sleeping Beauty</I> genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens
arising from common tumor-related mutations in key oncogenic genes, including <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#147;EasyWeb, Inc.&#148; in February
1999. We <FONT STYLE="white-space:nowrap">re-incorporated</FONT> in Delaware on May&nbsp;16, 2005 under the same name. On September&nbsp;13, 2005, we completed a &#147;reverse&#148; acquisition of privately held Ziopharm, Inc., a Delaware
corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we caused Ziopharm,
Inc. to merge with and into us and we changed our name to &#147;ZIOPHARM Oncology, Inc.&#148; As a result, Ziopharm, Inc. became the registrant with the SEC and the historical financial statements of Ziopharm, Inc. became our historical financial
statements. On January&nbsp;25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, or (as amended) our certificate of incorporation, with the Delaware Secretary of State to change our name to Alaunos
Therapeutics, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Office Location </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal
executive offices are located at 8030 El Rio Street, Houston, Texas 77054, and our telephone number is (346) <FONT STYLE="white-space:nowrap">355-4099.</FONT> Our internet site is www.alaunos.com. Information found on, or accessible through, our
website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#147;<I>Risk
Factors</I>&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2021 and in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the periods ended March 31, 2022 and June&nbsp;30, 2022, as updated by our subsequent filings with the SEC, which are incorporated by reference into this
prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations,
financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us
or that we currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are all statements contained in, or incorporate by reference, herein that are not historical fact, and in some cases can be identified by terms such as: &#147;anticipate,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;target,&#148; &#147;will&#148; and other words and terms of similar meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements are based on management&#146;s current beliefs and assumptions and on information currently available to management. These statements involve
risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that
the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be
certain. Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise substantial additional capital to fund our planned operations and repay our existing
indebtedness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of our product candidates, including statements regarding the initiation, timing, progress and
results of our preclinical studies, clinical trials and research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our product candidates through various stages of development, especially through pivotal
safety and efficacy trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that final trial data may not support interim analysis of the viability of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and Drug Administration,
or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to license additional intellectual property relating to our product candidates from third parties and
to comply with our existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the
results and potential benefits contemplated from relationships with collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations and licenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation of developments and projections relating to competition from other pharmaceutical and
biotechnology companies or our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunity for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated rate and degree of commercial scope and potential, as well as market acceptance of our product
candidates for any indication, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated amount, timing and accounting of contract liability, milestones and other payments under
licensing, collaboration or acquisition agreements, research and development costs and other expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position, including the strength and enforceability of our intellectual property
rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified employees and key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
the expected duration of disruption to key clinical trial activities, limitations on travel, quarantine and social distancing protocols, diversion of healthcare resources away from the conduct of or clinical trials, and other immediate and long-term
impact and effect on our business and operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with
respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;<I>Risk Factors</I>&#148; section
contained in this prospectus and any related prospectus supplement and free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may
cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking
statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of
the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to
reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of our securities offered by this prospectus. Unless we indicate otherwise in
the applicable prospectus supplement or in any related free writing prospectus we have authorized for use in connection with a specific offering, we anticipate that any net proceeds will be used for working capital and general corporate purposes. We
will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these
uses, we intend to invest the net proceeds in short-term U.S. treasury money market mutual funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of investors purchasing
securities in an offering under this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net tangible book value per share of our equity securities before and after the offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the increase in such net tangible book value per share attributable to the cash payments made by
purchasers in the offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock and provisions of our certificate of incorporation, and amended and restated bylaws, or bylaws, are
summaries. You should also refer to our certificate of incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our
authorized capital stock consists of 450,000,000 shares, comprised of 420,000,000 shares of common stock, par value $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.001 per share. As of August 29, 2022, there were 216,200,792
shares of common stock and no shares of preferred stock issued and outstanding. Our common stock is traded on the Nasdaq Global Select Market under the symbol &#147;TCRT&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> The holders of our
common stock are entitled to one vote for each outstanding share of common stock owned by such stockholder on every matter properly submitted to the stockholders for their vote. Stockholders are not entitled to vote cumulatively for the election of
directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. At any meeting of the stockholders, a
quorum as to any matter shall consist of the holders of a majority of the votes entitled to be cast on the matter, except where a larger quorum is required by law, by our certificate of incorporation or by our bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I> Holders of our common stock are entitled to receive ratably dividends and other distributions of cash or any other right or property
as may be declared by our board of directors out of our assets or funds legally available for such dividends or distributions. The dividend rights of holders of common stock are subject to the dividend rights of the holders of any series of
preferred stock that may be issued and outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights.</I> In the event of any voluntary or involuntary
liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred
stock outstanding at such time, the holders of such preferred stock may be entitled to distribution and/or liquidation preferences that require us to pay the applicable distribution to the holders of preferred stock before paying distributions to
the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences.</I> Holders of our common stock have no preemptive, conversion or subscription rights, and there
are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of
our preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock
Transfer&nbsp;&amp; Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;<I>Certain Provisions of Delaware Law, the Certificate of Incorporation and Bylaws</I>&#148; for a
description of provisions in our certificate of incorporation and bylaws which may have the effect of delaying, deferring or preventing changes in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of
incorporation, our board of directors has the authority, without stockholder approval, subject to limitations prescribed by law, to provide for the issuance of up to 30,000,000 shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in
each such series, and to fix the designation, powers, preferences and rights of the shares of each series and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not below
the number of shares of such series then outstanding. We have designated 250,000 shares of our preferred stock as our Series 1 Preferred Stock, none of which are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or
restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC,
the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if cumulative,
the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock,
including the conversion price (or manner of calculation) and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the
liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors could authorize the issuance of shares of preferred stock with terms and conditions
that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely
affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote separately as a
class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any series of preferred stock will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt.
While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental
indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the indenture that we will enter
into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which
this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be
incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of material provisions of the debt securities and the indenture
is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing
prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and
sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any negative covenants or other provisions designed to give holders of any debt securities protection against changes in our
operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture as &#147;discount
securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue discount,&#148; or
OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more
detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of debt securities being
offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether
conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive
would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that
restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, upon any such consolidation or merger (in each case, if Alaunos is not the survivor
of such transaction) or any such sale, conveyance, transfer or other disposition (other than a subsidiary of ours) the successor or acquiror must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an
event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given
by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and
accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect
to the series and its consequences if we have paid or deposited with the trustee a sum sufficient to pay all matured installments of principal and interest upon all the debt securities of that series that shall have become due otherwise than by
acceleration, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of
default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of
any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may
change an indenture without the consent of any holders with respect to specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;<I>Description of Debt Securities &#151; Consolidation,
Merger or Sale</I>;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;<I>Description of Debt Securities &#151; General</I>&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add
to the rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the
trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to
a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified
obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agent agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government
obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue
debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable
prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the
debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security
registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement the security
registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a
change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of less than all outstanding debt securities of the same series that may be selected for redemption and ending at the close of business on the day of the mailing; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are
specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this
provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities
that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date
to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us,
except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents
that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities will
be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_10"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related free writing
prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt
securities and be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply
generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the
warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the
registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or
the warrant agreement and warrant certificate, as applicable, that describe the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following summaries of material
terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements
applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any
related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon
such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any
time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the
warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants
represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the
applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent
for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or
otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities
purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_11"></A>CERTAIN PROVISIONS OF DELAWARE LAW, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CERTIFICATE OF INCORPORATION AND BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Directors&#146; Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate
of incorporation and our bylaws contain provisions indemnifying our directors and officers to the fullest extent permitted by law. In addition, as permitted by Delaware law, our certificate of incorporation provides that no director will be liable
to us or our stockholders for monetary damages for breach of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a
director for breach of certain fiduciary duties as a director, except that a director will be personally liable for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to be derived from relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of his or her duty of loyalty to the registrant or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This provision does not affect a director&#146;s liability under the federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that our directors, officers and controlling persons are indemnified under the provisions contained in our certificate of incorporation,
Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is therefore
unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions that May Have an Anti-Takeover Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions set forth in our certificate of incorporation, bylaws and in Delaware law, which are summarized below, are intended to enhance the
likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control.
In that regard, these provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have
the effect of discouraging others from making tender offers for shares of our common stock and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover attempts.
Such provisions also may have the effect of preventing changes in our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Blank Check Preferred Stock.</I> Our certificate of incorporation
contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, up to 30,000,000 shares of preferred stock in one or more series and, with respect to each such series, to fix the number of
shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other special rights, if any, and any qualifications, limitations
or restrictions, of the shares of such series. As a result, our board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of delaying, deferring or preventing a transaction or a
change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Meetings of
Stockholders.</I> Our bylaws provide that special meetings of stockholders may be called only by the board of directors. Stockholders are not permitted to call a special meeting of stockholders or to require that the board of directors call such a
special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Takeover Statute. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which regulates acquisitions of some Delaware corporations. In general,
Section&nbsp;203 prohibits, with some exceptions, a Delaware corporation that is a public company from engaging in any &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years following the date that
such stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (x)&nbsp;by persons who are
directors and also officers and (y)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to such date, the business combination is approved by the board of directors and authorized at
an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested shareholder&#148;
as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_12"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to
those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary, warrant agent, unit agent or similar intermediary maintain for this purpose as the &#147;holders&#148; of those securities.
These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities.
As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry
form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other
financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their
customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be
registered in the name of the depositary or its nominee. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary.
The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one
another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not
own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors may
choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For securities held in
street name, we or any applicable trustee, depositary or agent will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any
applicable trustee, depositary or agent will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their
customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the
obligations of any applicable trustee, depositary or agent and of any third parties employed by us or any such trustee, depositary or agent run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial
interests in global securities, in street name or by any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal
holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the legal holders to amend an indenture or other
governing instrument, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the legal holders, and not the
indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders subject to any contractual or legal obligation they may have. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued
in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under &#147;<I>Special Situations When a Global Security Will Be Terminated</I>.&#148; As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account
with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates
that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial institution and of the
depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain certificates for
his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank, broker or other financial
institution for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your bank, broker or other financial institution may require you to do so as well; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any
of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing
those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to have their
interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global security
that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the
institutions that will be the initial legal holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_13"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these
methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the times of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule 415 under the Securities
Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of The Nasdaq Stock Market LLC, or Nasdaq, or any other securities exchange or
quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than on Nasdaq or such other securities exchanges or quotation or trading services. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus we will provide a prospectus supplement or supplements (and any related free writing prospectus
that we may authorize to be provided to you) that will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options under which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more
transactions at a fixed public offering price or at varying prices determined at the time of sale. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or
commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting
agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Any public offering price and any discounts or concessions allowed or reallowed or paid
to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent
involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of
its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities. We may also authorize agents or underwriters to solicit offers from certain types
of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
provide agents and underwriters with indemnification against civil liabilities related to offerings, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to
these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at
any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as
the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim
a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would
otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on
Nasdaq in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price
limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive
market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise
prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_14"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities
offered by this prospectus, and any supplement thereto, will be passed upon by Covington&nbsp;&amp; Burling LLP, New York, New York. Any underwriters will also be advised about the validity of the securities and other legal matters by their own
counsel, which will be named in the prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_15"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Alaunos Therapeutics, Inc. as of December 31, 2021 and 2020 and the years then ended incorporated in this prospectus by reference
from the Alaunos Therapeutics, Inc. Annual Report on Form&nbsp;10-K for the year ended December 31, 2021 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon, incorporated herein by
reference, and have been incorporated in&nbsp;this prospectus and the registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_16"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities Act. This
prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer
you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to
provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date of
this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual,
quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including us. The
address of the SEC website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.alaunos.com. Information found on, or accessible through, our website is not a
part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus or part of any prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc309570_17"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-33038.</FONT> The documents incorporated by reference into
this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this document:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017022009942/tcrt-20220331.htm">March&nbsp;31,
 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017022017225/tcrt-20220630.htm">June 30, 2022</A>, filed with the SEC on May&nbsp;16, 2022 and August 15, 2022, respectively;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522001682/d263245d8k.htm">January&nbsp;4,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522017681/d173910d8k.htm">January&nbsp;26, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522077889/d332571d8k.htm">March&nbsp;
17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522079589/d332630d8k.htm">March&nbsp;18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522135461/d219505d8k.htm">May&nbsp;2, 2022</A> (first
filed only), <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522176544/d251784d8k.htm">June&nbsp;17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522182171/d383158d8k.htm">June&nbsp;
27, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522192331/d219766d8k.htm">July&nbsp;13, 2022</A> to the extent the information in such reports is filed and not furnished; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, which was filed with the SEC on March&nbsp;30, 2022, including any amendments or reports filed for the purpose of updating
such description. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Sections 13(a), 13(c), 14 or 15(d) of the
Exchange Act of 1934, as amended, prior to the termination of this offering, including all such reports and other documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus forms a part
and prior to the effectiveness of such registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the
date of the filing of such reports and documents. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be
incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered
with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You may request a copy of such documents at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8030
El Rio St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Houston, TX 77054 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Senior Vice President, Legal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(346) <FONT STYLE="white-space:nowrap">355-4099</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309570g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><FONT COLOR="#a03245"><B>The information in this prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#a03245"><B>Subject to completion, dated August 31, 2022 </B></FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>PROSPECTUS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309570g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Up to $50,000,000
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler&nbsp;&amp; Co., or Piper
Sandler, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Equity Distribution Agreement, pursuant to this prospectus, we may offer and sell shares of our common stock, $0.001 par value, having an
aggregate offering price of up to $50,000,000 from time to time through Piper Sandler acting as our agent. </FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our common
stock is listed on the Nasdaq Global Select Market under the symbol &#147;TCRT.&#148; On August&nbsp;29, 2022, the last reported sale price of our common stock was $2.47 per share. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Sales of our common stock, if any, under this prospectus will be made in sales deemed to be &#147;at the market offerings&#148; as
defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Piper Sandler will act as our agent on a best efforts basis and will use commercially reasonable efforts to sell on our behalf all of the
shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Piper Sandler and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Piper Sandler will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds of any
shares of common stock sold pursuant to the Equity Distribution Agreement. See &#147;<I>Plan of Distribution</I>&#148; for additional information regarding compensation to be paid to Piper Sandler. In connection with the sale of the common stock on
our behalf, Piper Sandler will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Piper Sandler will be deemed to be underwriting commissions or discounts. We have also agreed to provide
indemnification and contribution to Piper Sandler with respect to certain liabilities, including liabilities under the Securities Act and the Exchange Act of 1934, as amended, or the Exchange Act. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under
the heading &#147;</B><B><I><A HREF="#toc309570b_5">Risk Factors</A></I></B><B>&#148; on page&nbsp;6 of this prospectus and any similar section contained in any free writing prospectuses and under similar headings in the documents that are
incorporated by reference into this prospectus. </B></FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. A representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:-3%; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Piper Sandler </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022 </B></FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Prospectus </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #465361"><FONT COLOR="#465361"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_1">ABOUT THIS PROSPECTUS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_2">MARKET, INDUSTRY AND OTHER
DATA</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_3">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_4">THE OFFERING</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_5">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_6">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_7">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_9">DESCRIPTION OF CAPITAL STOCK</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_10">CERTAIN PROVISIONS OF DELAWARE LAW, THE CERTIFICATE
 OF INCORPORATION AND BYLAWS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_11">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_12">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_13">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_14">WHERE YOU CAN FIND MORE
INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc309570b_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_1"></A>ABOUT THIS PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus relates to the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the
Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell shares of our common stock. Under this prospectus, we may from time to time sell
shares of our common stock having an aggregate offering price of up to $50,000,000, at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common stock that we are offering, we urge you to
carefully read this prospectus, any prospectus supplement, and the information incorporated by reference as described under the headings &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation of Certain Information by
Reference</I>&#148; herein and therein. These documents contain important information that you should consider when making your investment decision. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents
incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus
that was filed with the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later
date (for example, a document incorporated by reference into this prospectus) the statement in the document having the later date modifies or supersedes the earlier statement. The information contained in this prospectus or any free writing
prospectus, or incorporated by reference herein or therein, is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus or of any sale of our shares of common stock. Our business, financial condition,
results of operations and prospects may have changed since those dates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating
risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We have not, and Piper Sandler has not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus, any prospectus supplement or in any free writing prospectus prepared by
or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell, or a
solicitation of an offer to purchase, the securities offered by this prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Unless the context indicates otherwise, references in this prospectus to &#147;Alaunos,&#148; or the &#147;Company,&#148;
&#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms refer to Alaunos Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We own or have rights
to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks
Alaunos<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, Ziopharm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and hunTR<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> as well as the graphic trademark found on our
website. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this prospectus are
listed without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks,
service marks and trade names. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_2"></A>MARKET, INDUSTRY AND OTHER DATA
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus and the information incorporated by reference herein contains estimates, projections and other
information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is inherently
subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from
reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. Although we believe these sources are reliable, we do not guarantee the accuracy or
completeness of this information and we have not independently verified this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of
data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_3"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated
by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this
offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus and the information included in any free writing prospectus that we
have authorized for use in connection with this offering, including the information under the heading &#147;Risk Factors&#148; in this prospectus on page 6 of this prospectus and in the documents incorporated by reference into this prospectus.
</I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Company Overview </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered
<FONT STYLE="white-space:nowrap">T-cell</FONT> therapies, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our novel
cancer mutation hotspot TCR library and our proprietary, <FONT STYLE="white-space:nowrap">non-viral</FONT> <I>Sleeping Beauty</I> genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens
arising from common tumor-related mutations in key oncogenic genes, including <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we are currently enrolling patients for
a Phase 1/2 clinical trial evaluating ten TCRs reactive to mutated <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I> from our TCR library for the investigational treatment of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung, colorectal,
endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our <FONT STYLE="white-space:nowrap">TCR-T</FONT> Library Phase 1/2 Trial. We announced the dosing of the first patient in this trial in May 2022 and expect to report
interim data in the second half of 2022. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In the United States, solid tumors represent approximately 90% of new cancer
diagnoses. Approximately 1.9&nbsp;million people are expected to be diagnosed with cancer in the United States in 2022 and approximately 609,000 people are expected to die from cancer in the United States in 2022. Some of the cancers we are
targeting in our <FONT STYLE="white-space:nowrap">TCR-T</FONT> Library Phase 1/2 Trial are expected to be among the most prevalent cancers diagnosed in the United States in 2022. In 2022, it is estimated that 236,740 people will be diagnosed with
lung and bronchus cancer, 151,030 will be diagnosed with colorectal cancer, 65,950 people will be diagnosed with endometrial cancer, 62,210 people will be diagnosed with pancreatic cancer, 19,880 people will be diagnosed with ovarian cancer and
approximately 7,400 people will be diagnosed with bile duct cancer. Mutations of the <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I> genes are commonly expressed across a wide variety of cancers. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The table below sets forth our multiple solid tumor pipeline programs. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309570g01a03.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program targeting solid tumors consists of: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>TCR Library</I>: We have built a TCR library that targets shared hotspot mutations known
to be one of the key causes of cancer. These are <FONT STYLE="white-space:nowrap">non-inherited</FONT> mutations. We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the National Cancer Institute, or the NCI, multiple TCRs derived from
third parties that are reactive to mutated <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. Our TCR library currently consists of ten TCRs targeting six solid tumor indications. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>Sleeping Beauty Genetic Engineering Technology</I>: Our proprietary <FONT
STYLE="white-space:nowrap">non-viral</FONT> genetic engineering technology utilizes a particular enzyme referred to as a transposase to cut and paste donor DNA referred to as a transposon into chromosomes of a T cell using a process called
transposition. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>hunTR</I><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP><I></I>&nbsp;(<B><U>hu</U></B>man
<B><U>n</U></B>eoantigen <B><U>T</U></B> cell <B><U>R</U></B>eceptor) <I>Discovery Engine</I>: Our robust and innovative TCR discovery engine enables us to rapidly identify new TCRs to add to our ever-expanding TCR library. Using our <I>hunTR
</I>discovery engine, we are able to analyze thousands of single T cells simultaneously using <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics and
next generation sequencing. We aim to maximize the breadth of our TCR library by evaluating both helper and killer T cells. The ability to continue discovering new TCRs has the potential to expand the applicable patient population for our ongoing
and future clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We believe our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program has
several potential advantages over other cell therapy approaches for solid tumors, including <FONT STYLE="white-space:nowrap">CAR-T</FONT> and tumor-infiltrating lymphocytes, or TIL. As compared to <FONT STYLE="white-space:nowrap">CAR-T,</FONT> these
potential advantages include that our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program targets intracellular and extracellular neoantigens whereas <FONT STYLE="white-space:nowrap">CAR-T</FONT> only targets extracellular antigens. As compared to
TIL, these potential advantages include that our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program has defined target specificity from the genetic engineering employed in manufacturing whereas in TIL there is no further genetic engineering
employed.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#147;EasyWeb,
Inc.&#148; in February 1999. We <FONT STYLE="white-space:nowrap">re-incorporated</FONT> in Delaware on May&nbsp;16, 2005 under the same name. On September&nbsp;13, 2005, we completed a &#147;reverse&#148; acquisition of privately held Ziopharm,
Inc., a Delaware corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we
caused Ziopharm, Inc. to merge with and into us and we changed our name to &#147;ZIOPHARM Oncology, Inc.&#148; As a result, Ziopharm, Inc. became the registrant with the SEC and the historical financial statements of Ziopharm, Inc. became our
historical financial statements. On January&nbsp;25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, or (as amended) our certificate of incorporation, with the Delaware Secretary of State to change
our name to Alaunos Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Office Location </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our principal executive offices are located at 8030 El Rio Street, Houston, Texas 77054, and our telephone number is (346) <FONT
STYLE="white-space:nowrap">355-4099.</FONT> Our internet site is www.alaunos.com. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this
prospectus. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_4"></A>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Common Stock Offered By Us </FONT></P></TD>
<TD><FONT COLOR="#465361">Shares of our common stock having an aggregate offering price of up to $50,000,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Common Stock Outstanding After This Offering </FONT></P></TD>
<TD><FONT COLOR="#465361">Up to 236,417,456&nbsp;shares, assuming the sale of up to 20,242,914&nbsp;shares of our common stock at a price of $2.47&nbsp;per share, which was the closing price of our common stock on the Nasdaq Global Select Market on
August&nbsp;29, 2022. The actual number of shares issued will vary depending on the sales price under this offering. </FONT></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Plan of Distribution </FONT></P></TD>
<TD><FONT COLOR="#465361">&#147;At the market&#148; offering that may be made from time to time through our agent, Piper Sandler. See &#147;<I>Plan of Distribution</I>&#148; on page&nbsp;18 of this prospectus. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Use of Proceeds </FONT></P></TD>
<TD><FONT COLOR="#465361">We currently intend to use the net proceeds from the sale of the securities offered hereby to fund the continued development of the product candidates in our pipeline, and for working capital, capital expenditures and
general corporate purposes. See &#147;<I>Use of Proceeds</I>&#148; on page 10 of this prospectus. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Risk Factors </FONT></P></TD>
<TD><FONT COLOR="#465361">Investing in our common stock involves significant risks. See &#147;<I>Risk Factors</I>&#148; on page 6 of this prospectus, and under similar headings in other documents incorporated by reference into this prospectus.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Symbol on the Nasdaq Global Select Market </FONT></P></TD>
<TD><FONT COLOR="#465361">&#147;TCRT&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">The number of shares of common stock to be outstanding after this offering is based on 216,174,542 shares of common stock outstanding as of June 30, 2022 and excludes in each case as of June 30, 2022: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">10,086,635 shares of common stock issuable upon the exercise of outstanding stock options
having a weighted-average exercise price of approximately $1.97 per share; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">22,922,342 shares of common stock issuable upon the exercise of outstanding warrants with a
weighted-average exercise price of $5.62 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">15,780,200 shares of common stock reserved for issuance pursuant to future awards under our
2020 Equity Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In addition, unless we specifically state otherwise, all information in this
prospectus assumes no exercise of outstanding stock options subsequent to June 30, 2022. </FONT></P>  <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_5"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below
and under the section titled &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 and in our most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended June 30, 2022, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of
the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value
of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair
our business operations. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>ADDITIONAL RISKS RELATED TO THIS OFFERING </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>You may experience dilution. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to
this offering. Assuming that an aggregate of 20,242,914&nbsp;shares of our common stock are sold at a price of $2.47 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on August 29, 2022, for aggregate
gross proceeds of $50&nbsp;million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $2.10 per share, representing the difference between our as adjusted net tangible book
value per share as of June 30, 2022 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options would result in further dilution of your investment. See the section entitled
&#147;<I>Dilution</I>&#148; below for a more detailed illustration of the dilution you would incur if you participate in this offering. Because the sales of the shares offered hereby will be made directly into the market or in negotiated
transactions, the prices at which we sell these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing shareholders, will experience significant dilution if we sell shares at prices
significantly below the price at which they invested. </FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>You may experience future dilution as a result of future
equity offerings. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In order to raise additional capital, we may in the future offer additional shares of our common
stock or other securities convertible into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per
share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other
securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>Our management might apply the net proceeds from this offering in ways with which you do not agree and in ways that may impair the
value of your investment. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We currently intend to use the net proceeds from this offering primarily to fund the
continued development of the product candidates in our pipeline, and for working capital, capital expenditures and general corporate purposes. Pending these uses, we expect to invest the net proceeds in short-term U.S. treasury money market mutual
funds. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or
in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">6
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">
significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the market price of our common stock.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>It is not possible to predict the actual number of shares we will sell under the Equity Distribution Agreement or the
gross proceeds resulting from those sales. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Subject to certain limitations in the Equity Distribution Agreement and
compliance with applicable law, we have the discretion to deliver instruction to Piper Sandler to sell shares of our common stock at any time throughout the term of the Equity Distribution Agreement. The number of shares that are sold through Piper
Sandler after our instruction will fluctuate based on a number of factors, including the market price of our common stock during the sales period, the limits we set with Piper Sandler in any instruction to sell shares, and the demand for our common
stock during the sales period. Because the price per share of each share sold will fluctuate during this offering, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with
those sales. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who
buy shares at different times will likely pay different prices. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Investors who purchase shares in this offering at
different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of
shares sold in this offering. In addition, subject to the final determination by our board of directors, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares
they purchase in this offering as a result of sales made at prices lower than the prices they paid. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">7
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus and the documents incorporated by reference herein contain forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in, or incorporate by reference, herein that are not historical fact, and in some cases can be identified by terms
such as: &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;target,&#148; &#147;will&#148; and other words
and terms of similar meaning. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">These statements are based on management&#146;s current beliefs and assumptions and on
information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently
known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to raise substantial additional capital to fund our planned operations and
repay our existing indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated
capital requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the development of our product candidates, including statements regarding the initiation,
timing, progress and results of our preclinical studies, clinical trials and research and development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to advance our product candidates through various stages of development,
especially through pivotal safety and efficacy trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the risk that final trial data may not support interim analysis of the viability of our
product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectation regarding the safety and efficacy of our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and
Drug Administration, or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to license additional intellectual property relating to our product candidates
from third parties and to comply with our existing license agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to enter into partnerships or strategic collaboration agreements and our
ability to achieve the results and potential benefits contemplated from relationships with collaborators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to maintain and establish collaborations and licenses;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectation of developments and projections relating to competition from other
pharmaceutical and biotechnology companies or our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our estimates regarding the potential market opportunity for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the anticipated rate and degree of commercial scope and potential, as well as market
acceptance of our product candidates for any indication, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the anticipated amount, timing and accounting of contract liability, milestones and other
payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">8
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our intellectual property position, including the strength and enforceability of our
intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to attract and retain qualified employees and key personnel;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectations regarding the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including the expected duration of disruption to key clinical trial activities, limitations on travel, quarantine and social distancing protocols, diversion of healthcare resources away from
the conduct of or clinical trials, and other immediate and long-term impact and effect on our business and operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from
current expectations include, among other things, those described the section titled &#147;<I>Risk Factors</I>.&#148; Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we
assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">You should refer to the &#147;<I>Risk Factors</I>&#148; section contained in this prospectus, any related free writing prospectus, and
under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our
forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place
undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">9
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_7"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50&nbsp;million from time to time. Because
there is no minimum offering price for the shares that we may offer from time to time, the actual total public offering amount, commissions to Piper Sandler and proceeds to us, if any, are not determinable at this time. There can be no assurance
that we will sell any shares under or fully utilize the Equity Distribution Agreement with Piper Sandler as a source of financing. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We currently intend to use the net proceeds from the sale of the securities offered hereby to fund the continued development of the product candidates in our pipeline, and for working capital, capital expenditures and general
corporate purposes. Pending these uses, we expect to invest the net proceeds in short-term U.S. treasury money market mutual funds. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under &#147;<I>Risk Factors</I>&#148; in this
prospectus and the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the
application of the net proceeds. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">10
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the
public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our net tangible book value as of June 30, 2022 was approximately $40,180,000 or $0.19 per share. Net tangible book value per share is
determined by dividing our total tangible assets (including our right-of-use lease assets), less total liabilities, by the number of shares of our common stock outstanding as of June&nbsp;30, 2022. Dilution with respect to net tangible book value
per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">After giving effect to the sale of 20,242,914&nbsp;shares of our common stock in this offering at an assumed offering price of $2.47 per
share, the last reported sale price of our common stock on the Nasdaq Global Select Market on August 29, 2022, for aggregate gross proceeds of $50&nbsp;million, and after deducting commissions and offering expenses payable by us, our as adjusted net
tangible book value as of June&nbsp;30, 2022 would have been approximately $88,330,000, or $0.37 per share. This represents an immediate increase in net tangible book value of $0.19 per share to existing stockholders and immediate dilution of $2.10
per share to investors purchasing our common stock in this offering at the assumed public offering price. The following table illustrates this dilution on a per share basis: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Assumed public offering price per share</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">2.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Net tangible book value per share of as of June 30, 2022</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Increase in net tangible book value per share attributable to this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">As adjusted net tangible book value per share as of June 30, 2022, after
giving effect to this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Dilution per share to investors purchasing our common stock in this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">2.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The above discussion and table are based on 216,174,542 shares of common stock outstanding as
of June&nbsp;30, 2022 and exclude in each case as of June 30, 2022: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">10,086,635 shares of common stock issuable upon the exercise of outstanding stock options
having a weighted-average exercise price of approximately $1.97 per share; </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">22,922,342 shares of common stock issuable upon the exercise of outstanding warrants with a
weighted-average exercise price of $5.62 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">15,780,200 shares of common stock reserved for issuance pursuant to future awards under our
2020 Equity Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In addition, unless we specifically state otherwise, all information in this
prospectus assumes no exercise of outstanding stock options subsequent to June 30, 2022. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The table above assumes for
illustrative purposes that an aggregate of 20,242,914&nbsp;shares of our common stock are offered during the term of the Equity Distribution Agreement with Piper Sandler at a price of $2.47 per share, the last reported sale price of our common stock
on the Nasdaq Global Select Market on August 29, 2022, for aggregate gross proceeds of $50&nbsp;million. The shares subject to the Equity Distribution Agreement with Piper Sandler are being sold from time to time at various prices. An increase of
$1.00 per share in the price at which the shares are sold from the assumed offering price of $2.47 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50&nbsp;million during the term of the Equity
Distribution Agreement with Piper Sandler is sold at that price, </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">11
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">
would increase our as adjusted net tangible book value per share after the offering to $0.38 per share and would increase the dilution in net tangible book value per share to new investors in
this offering to $3.09 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $2.47 per share shown
in the table above, assuming all of our common stock in the aggregate amount of $50&nbsp;million during the term of the Equity Distribution Agreement with Piper Sandler is sold at that price, would decrease our as adjusted net tangible book value
per share after the offering to $0.35 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $1.12 per share, after deducting commissions and estimated aggregate offering expenses payable
by us. This information is supplied for illustrative purposes only. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">To the extent that outstanding stock options outstanding
as of June 30, 2022 have been or may be exercised or other shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or
strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity, convertible debt securities or other securities exchangeable
for common stock, the issuance of these securities could result in further dilution to our stockholders. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">12
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_9"></A>DESCRIPTION OF CAPITAL STOCK
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>The following description of our capital stock and provisions of our certificate of incorporation, and amended and
restated bylaws, or bylaws, are summaries. You should also refer to our certificate of incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>General </B></FONT></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">As of the date of this prospectus, our authorized capital stock consists of 450,000,000 shares, comprised of 420,000,000 shares of common stock, par value $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.001
per share. As of August 29, 2022, there were 216,200,792 shares of common stock and no shares of preferred stock issued and outstanding. Our common stock is traded on the Nasdaq Global Select Market under the symbol &#147;TCRT&#148;. </FONT></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361"><I>Voting Rights.</I> The holders of our common stock are entitled to one vote for each outstanding share of common stock owned by such stockholder on every matter properly submitted to the stockholders for their vote. Stockholders
are not entitled to vote cumulatively for the election of directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they
should so choose. At any meeting of the stockholders, a quorum as to any matter shall consist of the holders of a majority of the votes entitled to be cast on the matter, except where a larger quorum is required by law, by our certificate of
incorporation or by our bylaws. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Dividend Rights.</I> Holders of our common stock are entitled to receive ratably
dividends and other distributions of cash or any other right or property as may be declared by our board of directors out of our assets or funds legally available for such dividends or distributions. The dividend rights of holders of common stock
are subject to the dividend rights of the holders of any series of preferred stock that may be issued and outstanding from time to time. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361"><I>Liquidation Rights.</I> In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available
for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding at such time, the holders of such preferred stock may be entitled to distribution and/or liquidation preferences that require us to pay the
applicable distribution to the holders of preferred stock before paying distributions to the holders of common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Rights and Preferences.</I> Holders of our common stock have no preemptive, conversion or subscription rights, and there are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our
preferred stock that we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The transfer agent and registrar for our common stock is
American Stock Transfer&nbsp;&amp; Trust Company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">See &#147;<I>Certain Provisions of Delaware Law, the Certificate of
Incorporation and Bylaws</I>&#148; for a description of provisions in our certificate of incorporation and bylaws which may have the effect of delaying, deferring or preventing changes in control. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">13
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Pursuant to our certificate of incorporation, our board of directors has the authority, without stockholder approval, subject to
limitations prescribed by law, to provide for the issuance of up to 30,000,000 shares of preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the
number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each series and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of
shares of any such series, but not below the number of shares of such series then outstanding. We have designated 250,000 shares of our preferred stock as our Series 1 Preferred Stock, none of which are outstanding. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the
qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the title and stated value; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the number of shares offered; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the liquidation preference per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the purchase price per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for
dividends; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
and, if cumulative, the date from which dividends will accumulate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our right, if any, to defer payment of dividends and the maximum length of any such
deferral period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the procedures for any auction and remarketing, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the provisions for a sinking fund, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the provision for redemption or repurchase, if applicable, and any restrictions on our
ability to exercise those redemption and repurchase rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any listing of the preferred stock on any securities exchange or market;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the terms and conditions, if applicable, upon which the preferred stock will be convertible
into common stock, including the conversion price (or manner of calculation) and conversion period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether the preferred stock will be exchangeable into debt securities, and, if applicable,
the exchange price, or how it will be calculated, and the exchange period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">voting rights, if any, of the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">preemptive rights, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">restrictions on transfer, sale or other assignment, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether interests in the preferred stock will be represented by depositary shares;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">a discussion of any material and/or special U.S. federal income tax considerations
applicable to the preferred stock; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">14
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the relative ranking and preferences of the preferred stock as to dividend rights and
rights upon the liquidation, dissolution or winding up of our affairs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any limitations on issuance of any class or series of preferred stock ranking senior to or
on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any other specific terms, preferences, rights, limitations or restrictions of the preferred
stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our board of directors could authorize the issuance of shares of preferred stock with terms and
conditions that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could
adversely affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to
vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">15
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_10"></A>CERTAIN PROVISIONS OF DELAWARE LAW,
</B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>THE CERTIFICATE OF INCORPORATION AND BYLAWS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Limitations on Directors&#146; Liability </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our certificate of incorporation and our bylaws contain provisions indemnifying our directors and officers to the fullest extent
permitted by law. In addition, as permitted by Delaware law, our certificate of incorporation provides that no director will be liable to us or our stockholders for monetary damages for breach of certain fiduciary duties as a director. The effect of
this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director for breach of certain fiduciary duties as a director, except that a director will be personally liable
for: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the benefits to be derived from relationships with our collaborators;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any breach of his or her duty of loyalty to the registrant or its stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">acts or omissions not in good faith which involve intentional misconduct or a knowing
violation of law; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the payment of dividends or the redemption or purchase of stock in violation of Delaware
law; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any transaction from which the director derived an improper personal benefit.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This provision does not affect a director&#146;s liability under the federal securities laws. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">To the extent that our directors, officers and controlling persons are indemnified under the provisions contained in our certificate of
incorporation, Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and
is therefore unenforceable. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Provisions that May Have an Anti-Takeover Effect </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Certain provisions set forth in our certificate of incorporation, bylaws and in Delaware law, which are summarized below, are intended to
enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change
of control. In that regard, these provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions
could have the effect of discouraging others from making tender offers for shares of our common stock and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover
attempts. Such provisions also may have the effect of preventing changes in our management. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Blank Check Preferred
Stock.</I> Our certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, up to 30,000,000 shares of preferred stock in one or more series and, with respect
to each such series, to fix the number of shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other special rights,
if any, and any qualifications, limitations or restrictions, of the shares of such series. As a result, our board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of
delaying, deferring or preventing a transaction or a change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">16
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Special Meetings of Stockholders.</I> Our bylaws provide that special meetings of
stockholders may be called only by the board of directors. Stockholders are not permitted to call a special meeting of stockholders or to require that the board of directors call such a special meeting. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Delaware Takeover Statute. </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which regulates acquisitions of some Delaware corporations. In general, Section&nbsp;203 prohibits, with some exceptions, a Delaware corporation
that is a public company from engaging in any &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years following the date that such stockholder became an interested stockholder, unless: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">prior to such date, the board of directors of the corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">on consummation of the transaction that resulted in the stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned
(x)&nbsp;by persons who are directors and also officers and (y)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
exchange offer; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">on or subsequent to such date, the business combination is approved by the board of
directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Section&nbsp;203 of the DGCL defines &#147;business combination&#148; to include: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any merger or consolidation involving the corporation and the interested stockholder;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any sale, transfer, pledge or other disposition of 10% or more of the assets of the
corporation involving the interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">subject to certain exceptions, any transaction that results in the issuance or transfer by
the corporation of any stock of the corporation to the interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the receipt by the interested stockholder of the benefit of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In general,
Section&nbsp;203 defines an &#147;interested shareholder&#148; as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such entity or person. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">17
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_11"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We have entered into the Equity Distribution Agreement with Piper Sandler, as our sales agent, pursuant to which we may issue and sell
from time to time shares of our common stock having an aggregate offering price of up to $50,000,000 through Piper Sandler. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus only relates to up to $50,000,000 of shares of our common stock that we may issue and sell from time to time under the
Equity Distribution Agreement. We will be required to file another prospectus or prospectus supplement in the event we want to offer more than $50,000,000 in shares of our common stock in accordance with the terms of the Equity Distribution
Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Piper Sandler will use commercially reasonable efforts to sell on our behalf all shares of our common stock
requested to be sold by us, consistent with its normal trading and sales practices, under the terms and subject to the conditions set forth in the Equity Distribution Agreement. We may instruct Piper Sandler not to sell our common stock if the sales
cannot be effected at or above the price designated by us in any instruction. We or Piper Sandler may suspend the offering of our common stock upon proper notice and subject to other conditions, as further described in the Equity Distribution
Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Upon delivery of a placement notice, and subject to our instructions in that notice and the terms and conditions
of the Equity Distribution Agreement generally, Piper Sandler may sell our common stock by any method permitted by law that is deemed to be an &#147;at the market offering&#148; as defined in Rule&nbsp;415(a)(4)&nbsp;promulgated under
the&nbsp;Securities Act, including sales made directly on or through the Nasdaq Global Select Market or on any other existing trading market for our common stock. Piper Sandler will provide written confirmation to us no later than the opening of
trading on the Nasdaq Global Select Market on the day following each day in which our common stock is sold under the Equity Distribution Agreement. Each such confirmation will include the number of shares of our common stock sold on such day, the
volume-weighted average price of the shares sold, the net proceeds to us and the compensation payable by us to Piper Sandler in connection with such sales. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will pay Piper Sandler commissions for its services in acting as sales agent in the sale of our common stock. Piper Sandler will be
entitled to compensation in an amount equal to 3.0% of the gross sales price of all common stock sold through it as sales agent under the Equity Distribution Agreement. We have also agreed to reimburse Piper Sandler for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;out-of-pocket&nbsp;reasonable</FONT></FONT> fees and disbursements of its legal counsel, in an amount not to exceed $75,000, in connection with the establishment of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">this&nbsp;at-the-market&nbsp;offering</FONT></FONT> program. In accordance with Financial Industry Regulatory Authority, Inc. Rule&nbsp;5110, these reimbursed fees and expenses are deemed
sales compensation in connection with this offering.&nbsp;We estimate that the total expenses for this offering, excluding compensation and reimbursements payable to Piper Sandler under the terms of the Equity Distribution Agreement, will be
approximately $350,000. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Settlement for sales of our common stock will occur on the second business day following the date on
which any such sales are made, or on some other date that is agreed upon by us and Piper Sandler in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an
escrow, trust or similar arrangement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will report at least quarterly the number of shares of our common stock sold
through Piper Sandler, as sales agent, under the Equity Distribution Agreement, and the net proceeds to us in connection with such sales. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">Piper Sandler and its affiliates may in the future provide various investment banking, commercial banking, fiduciary and advisory services for us for which they may receive, customary fees and expenses. Piper Sandler and its
affiliates may from time to time engage in other transactions with and perform services for us in the ordinary course of their business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">18
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In connection with the sale of our common stock on our behalf, Piper Sandler will be
deemed to be an underwriter within the meaning of the&nbsp;Securities Act, and the compensation paid by us to Piper Sandler will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Piper Sandler against specified
liabilities, including liabilities under the&nbsp;Securities Act, or to contribute to payments that Piper Sandler may be required to make because of such liabilities. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The offering of our common stock pursuant to the Equity Distribution Agreement will terminate upon the termination of the Equity
Distribution Agreement. The Equity Distribution Agreement may be terminated by Piper Sandler or us at any time upon specified prior written notice. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Any summary of provisions of the Equity Distribution Agreement above does not purport to be a complete statement of the Equity
Distribution Agreement terms and conditions. A copy of the Equity Distribution Agreement is filed as an exhibit to the registration statement of which this prospectus forms a part. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">19
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_12"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The validity of the common stock offered by this prospectus will be passed upon by Covington&nbsp;&amp; Burling LLP, New York, New York.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York, is counsel for Piper Sandler in connection with this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_13"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The financial statements of Alaunos Therapeutics, Inc. as of December 31, 2021 and 2020 and the years then ended incorporated in this
prospectus by reference from the Alaunos Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2021 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon,
incorporated herein by reference, and have been incorporated in&nbsp;this prospectus and the registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set
forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference herein. We have not authorized anyone else to provide you with different information. We are
not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus, regardless of the time of
delivery of this prospectus or any sale of the securities offered by this prospectus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We file annual, quarterly and current
reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Copies of certain information filed by us with the SEC are also available on our website at www.alaunos.com. Information contained in or
accessible through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc309570b_15"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The following
documents are incorporated by reference into this document: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;30, 2022; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal
quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017022009942/tcrt-20220331.htm">March&nbsp;
31, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1107421/000095017022017225/tcrt-20220630.htm">June&nbsp;30, 2022</A>, filed with the SEC on May&nbsp;16, 2022 and August 15, 2022, respectively;
</FONT></P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC
on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522001682/d263245d8k.htm">January&nbsp;4, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522017681/d173910d8k.htm">January&nbsp;
26, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522077889/d332571d8k.htm">March&nbsp;17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522079589/d332630d8k.htm">March&nbsp;
18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522135461/d219505d8k.htm">May&nbsp;2, 2022</A> (first filed only), <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522176544/d251784d8k.htm">June&nbsp;
17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522182171/d383158d8k.htm">June&nbsp;27, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522192331/d219766d8k.htm">July&nbsp;13, 2022</A> to
the extent the information in such reports is filed and not furnished; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">20
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the description of our common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021, which was filed with the SEC on March&nbsp;30, 2022, including any amendments or reports filed for the purpose of
updating such description. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">All reports and other documents we subsequently file pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such reports and documents filed with the SEC after the date of the initial filing of the registration statement of which this prospectus forms a
part and prior to the effectiveness of such registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus
from the date of the filing of such reports and documents. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed
to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </FONT></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this
prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You may request a copy of such documents at no cost, by writing or telephoning us at the following address or
telephone number: </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Alaunos Therapeutics, Inc. </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">8030 El Rio St. </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Houston, TX 77054 </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Attention: Senior Vice President, Legal </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">(346) <FONT STYLE="white-space:nowrap">355-4099</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this
prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus,
modifies or supersedes such statement. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">21
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Up to $50,000,000 </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>ALAUNOS THERAPEUTICS, INC. </B></FONT></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g309570g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>PROSPECTUS </B></FONT></P><center>
<P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361;width:20%">&nbsp;</P></center> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#465361"><B>Piper Sandler </B></FONT></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022
</B></FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the fees and expenses, other than underwriting compensation, payable in connection with the registration of securities
hereunder. All amounts are estimates except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents registration fee applicable to amount included in prospectus for $200 million in shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated expenses are not presently known. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Subsection (a)&nbsp;of Section&nbsp;145 of the General Corporation Law of the State of Delaware,
or the DGCL, empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in
connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsection (b)&nbsp;of Section&nbsp;145 of the DGCL empowers a
corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that
the person acted in any of the capacities set forth above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in
good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all
the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the
defense of any action, suit or proceeding referred to in subsections (a)&nbsp;and (b) of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees)
actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification
provided for by Section&nbsp;145 shall, unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#146;s heirs,
executors and administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising
out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides that a corporation&#146;s certificate of incorporation may contain a provision eliminating or limiting the
personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of
the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL or
(iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the
indemnification of our directors and officers to the maximum extent permitted by applicable law, and our bylaws, as amended, provide for the indemnification of our directors, officers, employees and other agents to the maximum extent permitted by
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors, whereby we have agreed to indemnify our directors to the fullest extent
permitted by the DGCL, including advancement of expenses incurred in legal proceedings to which the director was, or is threatened to be made, a party by reason of the fact that (i)&nbsp;such director is or was a director of the Company,
(ii)&nbsp;such director acted while a director, officer, employee or agent of the Company, or (iii)&nbsp;such director was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise. At present, there is no pending litigation or proceeding involving a director of the Company regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in
claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a directors&#146; and officers&#146; liability insurance policy that indemnifies the our directors and officers
against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description of Document</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex12.htm">Equity Distribution Agreement dated August 12, 2022 by and between the Registrant and Piper Sandler&nbsp;&amp; Co. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, and all amendments thereto. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm">Amended and Restated Bylaws of the Registrant, dated as of September&nbsp;
21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> SEC File <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038,</FONT> filed September&nbsp;22, 2020).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Certificate and Certificate of Designations of Preferred Stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex42.htm">Form of Indenture between the Registrant and one or more trustees to be named therein. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Debt Securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex44.htm">Form of Common Stock Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.5*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex45.htm">Form of Preferred Stock Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.6*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex46.htm">Form of Debt Securities Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex51.htm">Opinion of Covington&nbsp;&amp; Burling LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex52.htm">Opinion of Covington&nbsp;&amp; Burling LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1****</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d309570dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex51.htm">Consent of Covington&nbsp;&amp; Burling LLP (included as part of Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456dex52.htm">Consent of Covington&nbsp;&amp; Burling LLP (included as part of Exhibit 5.2). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522220066/d286456ds3.htm#sig">Power of Attorney (included on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;25.1***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility of Trustee under the Debt Indenture.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;107****</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d309570dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment or by a report filed under the Securities Exchange Act of 1934, as amended, and
incorporated herein by reference, if applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed pursuant to Section&nbsp;305(b)(2) of the Trust Indenture Act of 1939 at the time of an offering of
debt securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">****</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant
hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;);
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration
statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in this registration statement
or any material change to such information in this registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that paragraphs (a)(1)(i), (a)(1)(ii) and
(a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or
Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is
part of this registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities
Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in
the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
effective date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of such undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, such undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of such undersigned registrant relating to the offering required to be filed pursuant to Rule
424; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of such undersigned registrant or used or referred to by such
undersigned registrant; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing prospectus relating to the offering containing material
information about such undersigned registrant or its securities provided by or on behalf of such undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iv) any other communication
that is an offer in the offering made by such undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s
annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of the registration
statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it
was declared effective; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) for purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection
(a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act of 1939 (the &#147;Trust Indenture Act&#148;) in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section&nbsp;305(b)(2) of the Trust
Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on this
31st day of August, 2022. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALAUNOS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer<B> </B></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement
has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director <I>(Principal Executive Officer and Principal Financial Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Wong</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Wong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Finance <I>(Principal Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher
Bowden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James
Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert W.
Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mary
Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jaime
Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Holger
Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 31, 2022</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">*By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attorney-in-Fact</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-size:10pt">August 31, 2022</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d309570dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Amendment No.&nbsp;1 to the Registration Statement No. 333-266841 on Form S-3 and related Prospectus of
Alaunos Therapeutics, Inc. of our report dated March&nbsp;30, 2022, relating to the financial statements of Alaunos Therapeutics, Inc. and its subsidiaries appearing in the Annual Report on Form 10-K of Alaunos Therapeutics, Inc. for the year ended
December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to our firm under the heading &#147;Experts&#148; in such Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ RSM US LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;31, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>3
<FILENAME>d309570dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">S-3</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Table 1: Newly Registered Securities </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Type</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Class&nbsp;Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Calculation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rule</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;Maximum&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price Per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Unit</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;Registration&nbsp;Fee&nbsp;</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="4" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common&nbsp;Stock,&nbsp;par&nbsp;value $0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;Rule&nbsp;457(o)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Preferred Stock, par value $0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Rule&nbsp;457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Debt</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Debt Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Rule&nbsp;457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Warrants</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Rule&nbsp;457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ROWSPAN="5" VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Unallocated (Universal) Shelf</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Rule&nbsp;457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;$200,000,000&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;$200,000,000&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;0.0000927&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;$18,540&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000"><B>Total Offering Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">$200,000,000&nbsp;(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">$18,540</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000"><B>Total Fees Previously Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">$18,540</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000"><B>Total Fee Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">$&#151;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>Net Fee Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$&#151;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An indeterminate number or aggregate principal amount, as applicable, of securities of each identified class is
being registered as may from time to time be offered on a primary basis at indeterminate prices, including an indeterminate number or amount of securities that may be issued upon the exercise, settlement, exchange or conversion of securities offered
hereunder. Separate consideration may or may not be received for securities that are issuable upon conversion of, or in exchange for, or upon exercise of, convertible or exchangeable securities. Pursuant to Rule 416 under the Securities Act of 1933,
as amended, or the Securities Act, this registration statement shall also cover any additional securities of the registrant that become issuable by reason of any splits, dividends or similar transactions or anti-dilution adjustments.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee. Subject to Rule 462(b) under the
Securities Act, the aggregate initial offering price of all securities issued by the registrant pursuant to this registration statement will not exceed $200,000,000. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g309570g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309570g01a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#Z^8@8X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 6+)-P         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              #C   "<
M   !                          $              G    #C
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   #C     %)G
M:'1L;VYG   "<     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    XP    !29VAT;&]N9P   G     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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ME5OK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M /_A/TEH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX
M.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D
M;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ
M-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P
M.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,#@M,#14,#,Z,C Z,S(K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L
M/DUI8W)O<V]F=,*N($]F9FEC92!7;W)D(#(P,#<\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C(M,#@M,#14,#,Z,S Z
M,3<K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(R+3 X+3 T5# S.C,P.C$W*S U.C,P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9" R,# W/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^1&5L=&$\+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD8SIF
M;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @
M(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#I$,C$S1$$W,3<W,3-%1#$Q.3DT,T)#,39!-S5#
M14(R,3PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#I#13$S1$$W,3<W,3-%1#$Q.3DT,T)#,39!-S5#14(R
M,3PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.D-%,3-$03<Q-S<Q,T5$,3$Y.30S0D,Q-D$W
M-4-%0C(Q/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#I#13$S1$$W,3<W,3-%1#$Q.3DT,T)#,39!-S5#14(R,3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP
M."TP-%0P,SHR.#HT-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D0Q,3-$03<Q-S<Q,T5$
M,3$Y.30S0D,Q-D$W-4-%0C(Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(R+3 X+3 T5# S.C,P.C$W*S U
M.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#I$,C$S1$$W,3<W,3-%1#$Q.3DT,T)#,39!-S5#14(R,3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTP
M."TP-%0P,SHS,#HQ-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I$,3$S1$$W,3<W,3-%1#$Q.3DT
M,T)#,39!-S5#14(R,3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I#13$S1$$W,3<W,3-%1#$Q.3DT
M,T)#,39!-S5#14(R,3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D-%,3-$03<Q-S<Q
M,T5$,3$Y.30S0D,Q-D$W-4-%0C(Q/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P
M.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB
M=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_  !$( -T"7@,!$0 "$0$#$0'_Q  ?   " 00# 0$
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M8G*")28T-6.2HD1&5&1SDS96LE5T@\+CA925EL/$TM/B_]H # ,!  (1 Q$
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M +7 6=1&2Q[,#O?0](W6"H&(JNT$5*9/_"/[JQ:1=GNS'%E7T)^BND03U*R
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M!G2<\HEKLX<N'D8@>8/7S)^N_5@8/^,&[C][?/[8[!N-_P#:#GO]>O+&57O
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M.'\]Q@_L8]$L =5\D&>QZ6B=FSD$GE'%S#',%KRS*UNU7^/UAW:G)PP>OC?
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M?1\._P#\LUQ<SMQPE>A+T8*_]Q^C]U#^_P#25O$9T18Q[IPAS!ZZC?6K5<K
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MZ')N=L5OP@]=L-K7JL P.=1;N<D$ ,U>9O(ALYQW\T^DGK"'=-8'=JM*8_\
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MGC2OTF]-$G+U*E32P*U=I2)2DNULJ%/%@KG+N=.9]!WHM445#U3R%-.7/:*
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M/"IU*"JBE"G3)(8CM':[F\\8EXL^/O4KJ:F[%#<>TO!N".0N^$01CI)R' )
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M/6+TLY?-],KRO2G378T,YZOK3E,O4I)13R-"JHT$#)*4@^L9A6NH3HJ%!"1
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M>J4*;EZY)08,I\WP9F57 \6-[,:O5OJO73IS?1O1>5RB%@5\Q1SZZJJ8"DE
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MLQ3K98K *J2DY,:%4D.I2% Z@4DR&-L2NE=N2VG=RW=6M.=))>^ZE*VG%I5
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MNILC6X,=A+1Z;-3"EJ7'6I24IAH]D+45!*0<J''N]5:'5O,=)989U=0TU5$
M"IEJJ0>\"=1UI9(F21Y7QSWKGF.M>4ZK])9C)) KTLG76@TZM*HM&E)2]-'9
MJ*EMI&D#41: <;^7Q;'*;7;7O15(CTRU:[;&H%NT6IW+;=KU28DHL")69F#!
MD*/2*E/JBQX2Y2&92N526/S>J(!,0$@%!X[;TKT%U!K4Z1I5Z*:B<SEP--.J
M4A0JG2DI]8+!WUDG2TZ0#C\C]5.MOI:3G5C,4^DJE%71^>6@5J=&G4*DY8+"
MU+]20E1!+T:80I142E2E'%R7/R]Z(P8-_6TB+;$&_+IK54N;2RAR]8E)*IQ[
M9M$2J46]3?7(L6GH7>4O K!$6<BPQ)1S+Q4OT)/'O+ZK]6SVB-64UK5JI_W@
M D)=P!VY?620PL4B"^/"3Z3/2F:>6S!SW32Z%"GV69T]&TE!*ZS$+61DG^YT
MH$ @FJH$]TG%T3VCFE7S/>ER4^R;0EPNUJ<;2M!=JSU;N^FS<E=4W2:E"K-K
M0;D2JOKFJ9%FS3J[!CPI28EXB:S&E#X*4+RYWH#J_2RF=JTQE"JCDZZZ2$JU
MJ!II4 =(K/444ZV+%SMJ2&JH=?\ TCKK9.EGNDNF_5*F?I?:&8]4III+HU$!
M=9**GJ#(1VB:9[('4E(4 0A1?3#3*R:'=6G_ #%S%3LB#,7?0*3.5.C5TS9D
MY.CSJJQ&5&IE$D8L8)3,QH4-)@I4F-'D:?(H@IB'J#\VIY7HA>7S"C10I;$C
M25L"5FP-0D I8BS6;?'?NLF>.4Z\>C:C0Z9Z1.3S'V=3S1^RRL*24*95>LE)
M2E:*@3VB>ZY5J+ ,=1(D11F2E"3DL2HA,2"(?LJAQ%D?C/;[/[P_;F^?&13F
MZHH4U ( 8Z:G>5+H4YT@,'U L\,^._=$L>E>D2,UF,R49"B$TZV5-&D5]JH
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MNC,[F:3@KH=CFE=M/==**&HZ20J&9@=B#)/6[J%J2K^*>JKI!"%?;O1+I#,
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M]8DY.7A)]HQ9B:F9*% @PTA)*HD5:0D $G;@/5+K8Y_N&8V_RJP) BW9.Q+
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M)KT^U57$4OZ(:BY@B 9A5#NI4S$DP3TR418E"Z(W4KK?;H <.QN1T!UP!/\
M=LV7 <E%<J(&IDG[II<3M!?$#TWZ/J83_P!9>J@&HJT_;?1( 6"'4 <VQ4"7
MU!B+R^ :=ZL%*(7T2U*1!0AX<)5$NI2(20[P D2I!2D.P?N=^S^PNN3,,OG
M ' T5W\&[+]IQ$].^CX$K'67JF23J)^W>B-1)B_K;V>;P.&./#TXU1>-TV7J
M E,8_C6MBY40XK!@(J!*/$44O[1&$N';B!Z!ZX6]5S@!!=J54/:X[+G[W!Q8
M.L?4(*!/6?JL2F$MT]T4X$R#ZVX;=I=\5E:=ZJ+A"759FH/@A'2)6/;ES+E"
MAS^*3#]5]D*.0^SL!YP^P.N)#>KYPRP'95V/D*9V>W$6G#'6/J"%%8ZS]50M
MW4K[=Z)!F)/K>HEB1>6#VF,"P=5H2/ 19>HL*5Z"A4FF@W/ZLI&?Q @^J=!A
MG*@3W40^!Q54Z!ZU@Z:O06=SA2DM4&7SRPA/>'9CLJ6D)!*E,>\-6X4&Q5^L
M74<9JG5I]9NJCA 4%_;711(4"H!EC-DI+-SX-CC_ %;ZCD'ITZO1 2S0TVI7
MQT9'LL916V2X4Q)V#<5#J_UD!#=5LV ((]2Z0#18$T3!)/.^^/73UZZH9>DD
M?Q3U9( @GIWHLN6>"<P^TQOCBHL.^?7_ )L^A=UBJ>K">53!;U9$^F2,5, 3
MADO4S,"65&4((F/#$$Q%"&%]1Z>+D]6.M=5+IZ(S&5 =J2J&90?^+2NCJ8NS
M\1#-,$^D7J@L$#K3U8!$%NG>BB.1#YH<>&^.Q1IQJ5!4M<*Q;XAQ"P49>V[C
M@QG  'BD4\@AF;8@/Q =4^MR"Z<EF4D[A&82?"*+$$VCQQ&IUQZHYIM76;JP
ML 1JZ=Z)+7M_>B!SM\,0&G^JL)2BBS-0(<9O'5$@VU<85$*72E)C)DDDGI 1
MLX QCBU/5[KE1[J<KFTZ7D(K@EV,GL7=GN(>Y?&9?6?J84]FOK+U64 \*Z=Z
M*(8L6(];;G;^5(Z;ZG1(PF(]AWUXR@F(F8C6W<,69<Y!3',@J*DAP'6KV>GI
M'L@<1^P>N)45>J9LDEW4BNK;B:+B["WB", ZT]3$IT)ZS=5DH8C2GIWHM*1J
M<ED^M:0#,-?'*7I[JM,IZ9JS]0HT-2DH3"FJ!<\T?9#B(EY,(00<# ^RD>7%
MIZ"ZXJOE\X)9BBN>,N:7P+>6)T^L?4-#*'63JJA1!U:>G.B4$%P7)&:!+^7C
M<XBK3O5"+&3'79NH2YA Z(4R;8N14Q!2,"'XBI5X0W \+ !<Y/"^P.N&J<OG
M"P+*%*OJ8BP^Z! \-L-/6/J%I*?XGZJA*B24_;O1+*=M3@9QBY\RP\,5$Z?:
MK"*(AM'4B%&">A$RJB77$CF& PAPU^JGI0,=+@=LMQ:GH/KBP/JV<U" =%<^
M1/8L=R9:7G&8]-=0"5 =9.JH05$Z?MSHG0Y+N0,TQ):8X^.*433G5*.%(F[*
MU#F(2HD.*LS-NW-%6(L,]4#)E"5='<L?,G/#^PNN)<*RV<*3OHKEC!#-2!)=
MI']--+K%U I@!/6;JHDC8=/=%)9[R,W('D(M!:F-/=4H:I@+LK4 0YA87.I1
M;=SH3-Q0WA=4%,IX<1*2 "I>2Q*N_&4]5>MQ4L^J9SODJ/W>89;DFW9,I[L7
MYXR?Q1U*15[0=9>JQ*%*--7VYT22A)+ I)S;@$$#NFW$87U;:CD*4=/[V2$)
M5$6?HK7PF'#&5*4?4&"49=1("<DD<-/53K<ESZC7+O\ Y59W-X[&!??SMCTT
M^D'JC32QZU=6&$?]^]%0SB?[W(VL![YH2%@7W4Y6#/TRR[KJ4A-0X4:6G)*W
M*U-2<Q!C)*H,:!,R\E$@QH45(ZH<2'$4B(D**">*/X/ZV.5>H9J8_P *M<L
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MIEVZ.Z-=WM4&F;[1;B +XL'3.>AE(+,&U*=1E_Q1[Y:\P$KV!41G:-&![?\
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M#^"NAR(RHXOV-*W)T3'[MB)ZW9H%NQ6(%D5+D7/WA=^7 W=\,_*4YW8\H5$
MV;ZRXZ=VRQMP-N<LX(?MP#J5T*W_ &)!Y]A2<GQ"!.*U]8<[4)J %(-AWW81
M(U3Q][O@'RE*? ('*%1!ER3J9,YQV_<YM_HSP?P5T*/_ &%'_P!A3_5'SP?;
MV=+L3 #.I<\79=_EN1; /E*,\[_@B40O_-^LR/L&)27MP8\PV&?XV)ZE="$!
MLHD<!V%+?_\ -OO8D'QOC8GIO,Z$/50%,">^078W&OVF9P_F):7ZY4GM_P $
M.AL>IOWS([[]@+=?S#%P0!OMP_X+Z$9_5$#<O0IA^+?=C@>.,J^G,VE2F4"
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MD_B!XN5 VN,,Y 8NPW(&Q8'W[@N2&9_@%R(9R\&0VW>9AQ$F;/&%W20Y40P
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MN9(V!B<7)9@7<L(=M)<- B"[,;^['H)U,3UKB+.2I<5E15J<NN+TL"M1!*R
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MBI22E04$Q"004@L%!C[+ACG*2H!P"X/;AI]I+6U#R)(DF//CB%0**5!B.XH
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MZ9X+;M\[,P<=2026+OA@?:U*[K!X&FLG=@)#DL? D"""QZFL7!V[QT\=SH+
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M4^@N;Z6GF1 &SQ81QP_Z_P!?CP A[@_'Y$87LN[3#EXYC;YGE@W;X?#\OO\
MCGB%5F3R6D[<2(O#'GYXG14A2B M+Z%G9S >!8;;F9OA,24[_P *@$'R"T;>
M3E_+ 4279I5@#V478_R#CPW/E.*Z(+U#R4PM+B1S#O&PF,;!:8_R91V/KT]A
M@6_&I9@&V<'.WEL>.T=4RW1Z;N$HL5&"/>]W/Q;'&>MX?-D%O\908@,6)8@
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MB"'2H)#,T@ AB0)DN0\& QG" RS;IR0 &V9WR[@,1M@  .>+<J *JGV2'$"
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M<$E(W ,$'B&N[#O\2#V<Y'P&S!+/G#[<,,&?B&')BXY&"W >(Q)14 [NH@P
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MV_<,C3:=!1(5&WJ)'ILK(UJ<ARXE8<[+1X<2"LDE>RG0"F)=)+EB'8!G!)!
M-R/$6(PF^G.T^^WZXKP.;FY(,.VY-%IR=5G[HK\G:])7&GHDI,RM1D;UL?3^
MH52\I)$%<"WZ?5ZA<L2NT98453DLE*H*R@**4: !47( !('F1!DEMP!+<2Q>
MD.PDP6;9R0P/$ F!PWQ<"N9"[:Q2*5=5%H)A0Z.)6WKDMU9B^J+O*XM0(]AT
MSHJ,9 C1Z?)HI5:K)'0%&353C&*3%*1'LDB"3)CP"7G@#Q OQ:$1$<QO;PL9
MV>T6OQT<UUU3=7FZ$K367H\D+H^AD"OU>NRLG3I*HR\>)*3LW5Y:%$$_(TV8
MC0(IILVB$@19=<*)UCK!X?8 FY(9S$_0ON>(; P'RB+[#@Y\W;$93FCNBWX]
MYP+UIEJ3,M2*EJ]%M^/2:K'\-<CIM(TB>I-.F(TW!'B3E?14H_S:?X6:3**5
M!$16""AS4 UV+$$M,;.'$\>.'I<@S )M:TA[FW*WE4M/FOO"Z;@IDG$T]D:;
M0)ZN6Q)QJF*M$-5ATRZ-6:WHQ"FT2ZY4(,_+7!3I>J1('V4TU2HBCX8?C-QV
M^MG_ )X3"!?A^_CSB^-^.##P<&#$(A(AK(W"%$9;(!;/;/?MPQ</Q&$IPE1%
MP"WBT</GC\Y_TRE=K<EZ2_FF@2%=N&GR\:XK+F$P9*M5:G2\&;BZ::>P8\=,
MI(S,&$M<W!EXTL)CH*@4%U!@3]IT31IFFEPDB"Q8" ;G>\ @GDV/D<_GJ@60
M=0 44DN7:_=+[@-80UG?'F8+CNAP/I7=K8(_=3<6_M=C/9;+.P VX]NIDLNL
M .B7:UW&X!;>?EMFI9RH4D,HOS))!=BVHNY+-/PPA<-TG(NR[B3O^ZJXML?\
MN!&?S?GI^S\O=TMQ;?\ \K?'RQ8<Q58P7 8B ?!WV&P>;89N*Z1GZ6W=NQ2;
MJN/&3L?7L?=]^W ,AEWG20SOY;LG9WOA#,52+* ;V0! ES!M]!R< N*Z<DW;
M=P=V:Z[BP[?\M&,,S_<SG@/1^7'Y383#7GV?T<CRP_6*EF/Y1N[M9E?37>,(
MW%=+$&Z[M(_YU7'D]B/V:<9V9@VW;@]0RW%/N_\ ^<(UZKNRB&8F"21,]YMK
M#P+P</Z171D?2R[G!_[ZKC__ ,UG#=W^)QP_L_+G=/#9GX Z9]^&:]6YU,1'
MT"[P/"+3@-Q75D?2N[AC;Z4W$XWV:>'Q[\'V?E@+IM?PCAQ._+"%>M^4W$AI
M).\FS\;B.1](KJ.577=W=OW5W'D'_P"/=V)QCNS\+U#+#\N]]]R+;6V#'E!V
M]:6*G'@8)O=R2UCO'#%"8KEQ1H2H,S<US34M$2M$>7F[DKTQ+QX2T+AJA18$
M2<*(J8H4F&(920Z@6]G@'1] @^R8-F$MMW>)^7-DK,5AL0'8AO$)=B[0#&Q]
M_(-RW0H*2+MO-"D+B)41=5PK3,K$125S"QZZT-90(*>@, ?$8;._L_+NW=]T
MVX:?'Z@2[>J=E2P>Y,ECPO;9N+2?2.Z<DW=>"F&RKIN(9\PTZ'QN"/@-N Y#
M+L_<;;Z(N&/ZECA)KU79UN.08CB6.W$W:"<+Z272,?2N[G!<?NJN,]_,3N[,
M/TOW7V?EV<%+6GC_ .7Q(VL,,YBK((4)$L&$."7+7@<]L'TBNG'[K+NW)/[J
M[C 9@PQ.]S_3][^S\L-T\;<?+G'EM=&O4<N3XD#O  <PSN+E@6+C$3<5TAOW
M67>P)R;KN+?<;3NS/M\!ESPO4,O_ +38L!QX18N),^!P>L5=]0@EV;C%P;$,
MW.;X?TBNG 5=MW-U!C]*KB;W'^.D]^_P^+^S\N]TR>7[-]/AG,5;L6$BU]X>
MX'SQ(W#= <&[+N+D _NJN,-C!+3N-O+W\'V?E[NEKVY@1W9OQPO6*A<,HEQP
M]\*W\N#2!B)N*Z"7^EEW,Y=KKN/M@,\ZSOD#OG/"]0RW%.^W*]CX_P HP^WJ
MO8F18#B0X+\7F=^.#Z174["[+N8%\W5<>7R6/KOY?@<GN_L_+FQ3\F>TM'*9
MCS.WJARRH)8@3X29!+GA[H0N*X1&\0W+<ZICU6*GQ?I-78<VGJB(Z(/K?K?B
MF34DJB+@=13XZ82NDD$@/1]"XT[$,SSY;7'N.$,Q5)@&PAFD/N^PY>#3BJJX
M[H*BUWWB$@!*4FZ+A4P9L$SHV]_^CA'(9<!P4WX<BS'3'A#_ !P=O55=QXM!
M-_(;%[[%HIFXKH#/=UWG?)NJXDG&-A/,P #9'Y^#U"@Q]EY+ 7X1IVF1$X.W
MJ#\QB##%+[2T;!N0PS<=T @?2N[BSC^55Q/C#_QUP<C=F\QEP]'Y<;IMN.-I
M;Z\B,'K-6^DLX#P">)))V=M_GB(N*Z!U?NLN_<,UU7&Y <9/KK;?=Y'@]0RT
M2GZ_Y9D?/#%>J+!7(,'@6=[CG(?#^D-T._TKNXG&?I7<7],Z';OG^CA_9^78
MD%) \/T#X1K5B6TD2'=,\8(.\\X.&;CNC_OLNX])=_I5<7D3_GOO9FV/;A>H
M9< /I\;OYLWR/'!ZQ5-]428CG<[@PQ_3"^D=T[_2N[W?O=5Q#?;_  T.#C'P
M[D\/[/RYL4^X3/,>7 ;X?K-4BRB\.P+.T,"9)($_$LX;BNE_Y67>Q<8NNX^W
M?,]L2P9O>-N$>C\N-TW:P\]OJ, S%5F[W%V W>9X^&*BKDN8PD*7=UWK1$48
M41 NFX=T@]0(]>? \L8WX?V?EVC2.;<G=F_;D=L1.8J@V58P"X)+\XXFVS#$
M(5P7-!1"$O<]UPX('1!A2MS5V5E_59>(84O*)@PIP0Y:!!EBN/$Z0DJ *F42
M_#^SLO\ [0+VY3^&UX+M&YE>L5=PJ#!8.P(;FS%^,&</Z1W4W\L+Q<9!^D]Q
M,2'?_#<X;W<+U#+RVDV>+3:VY:+P9Q(UZK,Z@7A^,N+_ .TEX]J[%L9:T$YB
M-=]!]5K.U+TAOJ[$7W2I^7A4J3FJI5Z_*UJ*8J(4Q08U%FX\S"GI*IDB$F2$
M%<2"%]?4"EQEZ0Z/RXIF0Y'@0&+?AXN6%\&3S%8K#EA)GB"Y:6F-H#W#X_2N
MY8+_ -1-5]#=,]0-5;"FM,-0;EMFG5>Y;+FXJ8T2EU.+ AIBH2I)4(,O&4%Q
MX$HHB)!1$2E8!#'X+,TD"H4@@Z57&Q$D&.?$MCZ^B2I(47D".6S3 ;9ARQL;
MQ7B[!P8,'!@P<&#!P8,'!@Q^5-S$XYA>88X+:[:Y$#_Z3KVW]Q_+D\=.)N;R
M!N=DSOR;X3?XBH4D0HDZ23<!N\)AQQ,1P?%U\I&C%&Y@.8S2C16XZM5:%1-0
MKEEJ1/5.CB$JH2"(DK/32DR@B=:.B)ZLA)1%2>H86DNQJJK[*FJH[Z 26@J8
ML[D$%HV,^_&9%)=2JA(!8J3<CB[ O94[W\'&_?)9Z/'33F/H^J$S>E1NJ259
MFK]]Z;4FO0;@D*/087T:L^M5RE3E?DQ3YF>@F+&D8,:K1I#H@PI5,4H0M8"%
M>8KI1*4%2:@)[H 8AW(!N+L26X>$>Z,G5+ TS^(DZ@UGV+3 Y\ V,7U+T4NO
M5!M2HZ@5S4OE[ING*1:,2UM09[4.>E;;U$F+YIZHML0;*J4*WHDU,3=6C2<[
M1(DO.R\G$$]+QE1$(A%$93'2B"PU$:G3I((^8( #['_A!G$%Y2MI4"@LQ)5#
M,Q<W>0)N7:'..TF/1$\QU)A3]:KFH.@= L"EVA0+QBZGW!>==H5DU*C7/=$>
MQ9*31&F+8@U=,[*7#0DR4NJ9I\O#G9N=0N37&A+$4AZ50D%U*>Q2W>ADO,2"
M'GV0^,)R8!"2=M3FQ!YB2 H$,'<@D[G& -6.3#4+EJ$2YN8M$C2[,I>L472Z
M=D[<K4./=%W)DJ)2KEJUQZ?)J,F:=-6U,T&LTZ/*5696B&5S$.&$*C=4-,SG
MC4I*-)>HE+!C)-@[LS,;0X;"%!"%@F&D@@LT@M+6()#D$ <<;Y0_1[<H]V5?
M2BE6;>W,!;TE=F@5<YK+GK]V?0BJ0:)I3:<29AUF@R%.D9!46H7G.1$2T*G&
M%X5/3+1UKCQ 4$<9!FLS^("Y3W9&IB4NY@$7)W$,\[-%-AI!CO"P#3Q9R_[8
MZ'ERY,^3+F_.K57T#@<W-7&E5N6A-U#366.GT:[[BJMUWPBTI:9HM:G5BGF1
M128D:XZK*SAE13H$O&EY5<8@J#];S"-!64ID!2E>Q(59B[^>QVG#32U$Z4DA
MBP!#@B7))MQ8.3:YQKAJ+R>V]I!S!:B2=SR.K.IG)Y8M_5+3KZ]=,).AIAS=
MR09FET.G4>:J\]XE&74J17JM&H5PP1+(*HM.G1)J5%5*15ZT9Q50)%,C60%Z
M5&0EQJ"@XL.[$:IL[OL%)))!(/=)# &Y#'WR98\L=US9<G&F]B<W=/Y..64Z
MHW?J1)731[<K<UJ/.VY+4*L5"Y*'3+AI<:WH\A!$23DZ5*U%$G4XTXA*DA$2
M)+I4ECQJI5*S:ZW<IL3K#I#,2G=Y@;;/BBK3*0P"M0AA)86;9@0) Y.!CN;*
M]$KS*:H1KR1IC>.A]^REC3*K?GZ]:EZ5BM4Z8O9")V.NR8<27MLQH%<DER,>
M"N:J"):E0E^TJ?Z"%<9\QGT4P2"0_P"%1=I(?:\6+F'%\64,O44P""H@:0IQ
MWC<05-W0\_#?&3.>?T>FF7*]RKV1JW1)V\%:A5*\=/;5N&F52IPI^ARD:X=,
M9&[*Z98PX:5"(*W%CR\LI1^Q C$ I4E1QY;I!69S0H*(_,.X$GNEG)9W,%H;
M@&QIS6672RRUJ3I8L#JL2&:]S;<8\;DDJZ2P)"X8V=B5IP/@[]W=_=Q[U=P*
M9=R"DM<'9_@9/PC'@Y=4U"S#21P9W8.UB.$!\;":8/\ 1E&'/KL\06W_ !J2
M1WRP_*'.2W'9NJQ;H]))8:$ WX.X\99X%W..+=;U"GG#97WJ[@[NX\6#O);F
M^,BX )&QS^@/YX;/W\?5"0P\'WD._C(_KCY%*DE3 @Z[-(N"1;>P/# Z<C#X
M(\N[?##9&-ADLR/=]J'L]GD&P'$/S,3B80H]XI(22S'A/LAP 6+R"3?$3V [
M@^]@Y()+$Y!8>\^9X6I+ $N%.0WB?!QX"PYC"TZ568*!%G@%*P +B(F7;@^&
MXP-E.']^1Y8R.V>V<<(+2&=3#SV #$6N[L89SSEI+D27 D1)<D\^[I8,;,P:
M9$G;L7RV0S.QR21Y #<>_@UI,@AK[B;?(\C:>$"H @D@F'<2 7NSB#?FP=CA
M$NSEB^ 1]VV'_P IMP<]N+ Y!86O#$"\WV#_ +/B02JJ722P@&&!,L) Y@MY
M8B" HNSC&>P).<[[[[MGL>%H41($V;B1<W][_%L6IIU L@(4P82H$LF1?=@3
M'!C#G$@0Y8G=BX<@@$/VP2 W9OR!J(20\$@P\01XE]+GS;GB@C04I6H LX)>
M-04"J/PZG"2>#"^$DASE]F\_?^?MY#N.(&H@V4'-@':/ 1>9,-P. )TL"%$,
M)+R\B=BY8.>+EW>3G<#J&#D_?L>WY,]N_#*D@L\["2\;1\OUQ(*2SA1,N]S=
MK%H\0SG  <.P=_?DN&W+D.EG #MN,\(J3=]V'F1X1#&T/XX147 !#*U& Q.F
MXEI )*6$EIDN LH@*9@"7W.&)?;S9O>/M#BS+KIIJK<B4AKN20218V!!,,#(
MBU==%2I30R2TL6@A)TZG?NDLP8<02XQ[U_)^(\*7YE=78L58AH.DL!(*C@E-
MTTI2@-U8!=R!@CRQQKTJTEKI(*4E04L,S<7X@-[K/ QV#T9D(J@+.E02IRIR
M^Q8R6+^/*^/K7J,.W*O+Q9>KHIU3DHK!<C/0H<W+15)/XN)$E(\.*"8?VD10
M@L2SN_' THK).G009L6@F7:/<6/ 8[N6,@G8R_ 0Q:''['%O&VM/DK@(%"M\
M(A2,S(0BBER#2U/BE(F:9#'@=,.2GX:E0XLDE/@J28W6I/60J\&L!&IWX\F<
MS<.&/OM@!,Q;Q_4#YX['YGLL*C3,&G6^B9CIEQ,QDR,BB:B^K1/%E.N-ZNJ)
M,&1C(1-RXB)48,Q+RRX1AKA(*:]:P3)N[/OO8\ QY/SPM8#]Z0>8:P9VW_7<
M8YB(%J0$1H<.4I:8,:*)J) AT^53#7,)B&.F+$1X0*HR)J)%F4+4"I,9<184
ME2B2$KB39AWMM]XLQM:9PNT2Q+QX'ZEX:-WD8X4Q0K$FE3BIFE6Y,FHKAQ*E
M$C4R3B1J@M'V%32_ ZI@H'V1&*TH9@,#B0[79[-<6,\6F[^>):K-,:A^XYVX
M7QQHM L*9AJAQ:%:\<+C0HL2%&IM-CB)'@%D1E0?!=2T(@04PXK%:@$(B)Z4
M\#5; F7:>-_+X0XL^#WAK[P Y=N4O/Q(QVHE;2AQ$+A2M$0CJAQ$I13I5*X4
M:!4(54E%(*8 (]7J!FJBC(*9R*J83^,]KB.A9V^(_>\@,/<^%[[\#O?:W'YB
M,7!\]4IV]>@O\5?_ */ ::PSI9V:1O;?#<<_<?V^O(XE\\4MP/78+G;)R_O9
MN#LU_E/P?W8'?ZX8BNKTQ25I$[ )*5) *V#D$ .0!D^99G)P#P=FL3I(8.\0
MW],$&#O%COX#^F/"A?HQ^3?G'Y@^</5K7BT*U6[PI_, FTI.=I]WUFC2IH-,
MTGTKCR252TA&2A3*J,8DD= #K44I<CT*&>S%)*!2D =XD.Q M<!K$[RPF^#,
MY'*K+J(*B'WN2W!R1ML_PN]'H'?1D CJTXN10<,1J7<@8#!QZQL[[GW\55>F
M<X*J "94-X$E]Y#W$?&51Z+RX25!)( ?R\&+NUN%FG%<^@=]&(6_>XN1LCJ^
MLRY20[_\I#^8]SCX6_;&>_.GP(_8GP^IGZCEMT2S>R;/X/XWV\T/0-^C$#CZ
MN+E8]_K+N08. 6]9_P!/!]L9[=:?($_J,'J.6V01'Y3Y;6&P^@SZ!OT8;@C3
MBY&([ZE7*   VWK'O'EVR.X.F,_^9/NWEG8[#<<;'"]0RSOH$<$\(,M@_4'/
M1AL -.+E)PX&I=RC^;EOV0Q<;MV+\!Z8S_YT\H/[GB3X\7.'ZCEMD,+^R?/;
M?P? /0-^C$[Z<7*X?'UEW*-P[?QE\CWGN_N/MC/?G3Y#QF3?B/<\@GJ&6_)'
M#3;CLSGF/*2Z_4'/1ADDC3BY=V ^LNY&(]SS#M@?T<'VQGOSI\P?BQX\(^6%
MZAEMD?\ I+V;8#Y8?Z@YZ,1LZ;W+V.=2[DV[9]88@.WY'[<'VQGH[Z;!X_G/
M.W+#]1RP).B_^T@MS@F1'#QG&NO-IZ%WT=VE7+KJKJ%8^GUP0+HM>V(]3HT6
M/J'<,Q#3-PHL)$/JAQ9DAB5A(4 Z>H'">H\,=,9[=05_PB;<28%]IY0,/U#+
M*<:6O+0S6@3/Q@L,;"(] UZ,=1BF+IS=*5HC1 M]2;CA 1E(@B*.E$R4I+PD
MCH5E*D++,75,]+Y\V(2"1L]K'VG' F+[3A?9^7+. =V$#;AP@B3M.*@] WZ,
M-(8:<W*7\]3;EQ^68;]/Y@.('I?I #VA?@&/_J+6Y']$,AE@_<NWX/T #WQ+
M]0<]&&<G3BY2YR^I=R^R'P_[)\PX]_W<+[8ST]]'*#/QPSD<MNC_ -)O>./@
M/'; ?0.>C#S^]S<JG8@?65<@V<#/K)=V/OQL_!]L9Z.\F\Q8-X[?1P>HY;=!
M:89N4Q9F=^')L1_4'/1AG?3>X]R"#J7<I8@;?QC\FS-P_MC/#\:3XIO_ .KW
MQX/;!ZCEF]AWGV7$F-OY[[2_U!ST8>#]7%RD[#]\RY/Z)GMC;8??POMC/_G2
M/(^ZY\[%[%L'J.6_)-_9+1R;EQP_U!ST8CN=-[E&7)&I5RD8[L)C?_7[SP?;
M&?\ SH]Q_>P][<3@&1RVR 'O#/YM^\GGA?J#GHPG .G-RA]A]95R8WV/K.07
M![@9]_#^U\^9"@0[68?,GY>X' ,AEOR D6+3'$,_RN.,A] [Z,,$-IS<Q9/;
M4JY26!(<M,')WW!_I?VMGS^)(/A9QS5]'SP'(Y?= CD>8\_KEC73]1?]'<.:
MJ8TN7I]7TV9#T,5?8ES?]Q&83<@OBE42',B85,=2I?YMFYB&N$"Z8BT>R>&.
ME\^8+.-[ CW@NYW>V&<AEVA(#G83XG;S^6-BOU!WT8A)?3FY>I)4A75J5<J6
M*6RQF X&V,$9!\T>END+Z@UP&+WX/R;;FUP>H99V*+\KQ,LQM\&Q,>@<]&$=
MM.;D(R!^^5<A#X#_ ,8R[@=V(]_$3TQT@"1J$0S-Q??]>'/"]0RT=QQ!#)@>
M#"-[\??$>@<]&(20=.+E?#MJ5<C_ 'CUG+D/M[]L\!Z9S^RD[Q)^OA;R"]0R
MS2EY/X8/B&Y^]MP<,^@<]&'@'3BY'+[ZEW+VPY_9 ?[NW!]L9_\ .!R;^?S:
M=VP_4<L[Z;&0$W+;Q_2'POU!ST8;9TXN78A_K,N1]O=,M[OT\'VQGOSIYP?A
M,\[<C@]1R_Y/_2</]0<]&$SG3BY&V/[Y5RC#$.?V2'V\ML-C@/3&?V4G;;X7
MP>H99_8DAH3QYL8'!_'"_4'/1AO_ '.+D+9Z3J5<GD#WF<^;X##OP?;&?MK3
MXD3YL;1\=B['J.6V1<O[+[\A<6+SX'#'H'/1AG)TXN3L1^^7<APW_MG8,3^;
M9^#[8S_YDWV!8>\[V+"WE@]1RPLAO^4_H&LPQP)_T$7HQI>1GYB7TVN7QX$E
M.34)?UC7+T@IEUJ"\S#8"'QGXGA_;&==]087 $EA+26_E@.0RQ_"D20"0(^K
M\]L88Y;?0I>CDU#T,TOOFZK"N2;N2Y;3I=2K$26U$N.6@1)^/*!40PY-,R 4
MPX75U*9EE*OM*4!Q(]+YXRD_E;\1-@=V=X8-;G >C\OP'BT,+7#S<QO,#&<_
MU!OT81 _>ZN?&01J;<P)._:9P>^-O>0W"^UND+:AXZ!L!NY!YB9-L!Z/RQG1
M$W%O?:9V/-FQD[1'T0'H]>7[4"BZJ6'IG%CW7;D:+'HDW=]UU.YY*GU"+E<Y
M+R-9BKE!. CV8B@>DCV2[/G7TQG*P*%*-B5$"0"VY-SRQ:.CZ%/O)IAW/^X/
MX,Q^.QOCU)A5.1A%*/6H(AI6@PRE9V"&48B>E(0D;)0@$!@ PQQC)*C:3$;[
MN9WY^)Q<*51$MW21/(!W(-K0Q\L<[YYI>/V;!R[95V_^#Q+LU_EOS'[_ --\
M2<<X?8[>4X/GJEC_  V"WFZF[]^GW']'!V:RT7M(\./U>V!_'W']L K-+()$
M[!8;EU?_ *.?NX.S7^4_#][<[8;_ +V/UY7P&M4H;ST#9_M';\GYM^#LU_E.
M#A>>1^O/#^>*9_GL$X?!)QOV![9^&>#LU_E.!]OT/SMBI!J<A')3!FH40A(4
M0"<)+,<@>8X"A8_"?<_RPG'$8_*TYB?[X7F'?8:[:X.>W]T^]^^V-_TXSQTL
MP _)[[,Y'A?XX^":7?\ "[M>X(=@'@O"C%\2T!UFN/EWUBL'6FTY&C5>X=/Z
MP:U3J778<=5'J2DP8L!,I41+I\?VX<:)#,2"7 4>E:2 14I*:B%4S*5@ B6/
M$\6CCX[C$D+(4E0,@\#L0!+$!30[2)!&-^K<]*Y?%ARE2IFFO+7RUZ<T*NW5
M5KQNVA6S;ESQJ9>59N"BSM!K4>XI:>N7KG8T_3YZ/!7%AS4G[,0^RE\9/LQ)
M@PYB"&EV?7#E[2;''IC/U$CB!N6)(W;NFTN27]V+5N3TI6O-Q4>U;6D;+TJM
MRT+!U1T@U*TVL6U;5GC;ED1='*;,TVW;3H-%FIR>];MZJ*GYN?J\A$AQ)R9G
MIE:)>(5K1$X?V6G4/:8DAG(DFQ[Y;O,1<!X8$X/7U*&D)+$][D]PV@. Y@$,
M0YVQF>\><#GUY\-%-1].-/>5&HWMIK7I*BZ>U^L:)Z5ZB7?3[:A42^8FKD&F
MHK5/J5;I5.JB:W&CP)J16B:AP@M,)'@)1T)QYS)4J*P%%*2IU $A*E%.D%AK
MENX"=@4M< P"^T%B4CNN[@ EQX/WC9G#N1.,%^D?U)UZOZK\NUJZJZ4:RZ34
M/3#06WK(L6CZQ24:GWU=T6C2LM2KSO\ CT>'*QHT*2J4]*R4A)3<W"3,0Y"D
M2B8O2A75Q9E:-)*5,06)!8F#!(8$@&7:+ZF()<K4U]E46Q]@L6(AV X'<.0;
M /W6&)Z'SYZUVU>VAU_6RFV*-5=#-*YS12D2<.DHJ5$O.RYB)'^>*-=M-G#%
MEJW J$O-*$63(ERM318:T&$5HO[&E(8N2"0Q<6.Q!8:1 B/'&%%2HP[H  9X
M8LU@Q#N9<SQQD:/Z3'4>DVU?EJZ.Z5:!\O\ 2[RDK6,]-Z,6C&M:XZ'4[3OV
M6OZ#6_GA=:J54F)JK5J1EHT\BJQXM)EI!4S29=$JB<AQH33EZ:B$J45:BYE5
M@#8;6(8#F ^-J*JR4D)A@\O%F+<"TP![+[8UJURYC+AUTU:KNL5;I=K6E4KB
MJU!N:Z:':,"<I%F5"])&5I$U%N>?MQ=3GI>%,W#$]<J-?F(<2$J+6DI2(1C1
MH,.)>,M3HN$P2EG[Q)#M)-[<Q#D@OA5<PIDG5#Z@3I<*<&&EMNZ+D2;XN^].
M<;5R\^;"+SCI%#MS5N)<%N7 A5-IIBTF1C4"ARU!@2JY..M*9F%4I*FI,S+1
MO!3-2T5:TQ4H4B*9H":H.7(!00K4F8#1>2S3):S[XP5,U4U:@X+@\P),D $/
M+!I!'$XV/IOI1=0Z)+7E1;=T!Y<[=LJ]JG]*JC8]%M6O4JD2&H$2%-B/?LC,
MTBN4V;569I4[&,S3I]<Y2X@40M,4=(XJKY"FMC)8!+DN2!L25 WEQ+SQ.+Z&
M?4DR(Y, EGLP/!I9F@\,9<Q/I!=9.9C2&@Z.7Y0+"IUNT&O6W7X,Y;U&CR%4
M5,VK; M2G08<2).S<*!)*IZ51H\* B (T4P5K2I<,D9*603EZR:H>Y2!_P 1
M<NRE#<M'R&-M7/JS-!5)0 =U!WG3L.ZF'DL?*7QH>R1$4![*?%A]+C+!88MO
MW#@G9N/6KNU,'<ACS:[AW>UI!@F<>/1 !J7/=5S8.]B'8%M^1VQL'I@WT<AI
M<=1G9\I#'^:I"E-Y@)#GNV._'9.J[_9U-@/8IR=G38RX#[N1RQQOK@@+SA<J
M([6HIP 8#@FX#;QQQD93,Y!<$$]/M!(4"0H]'4R$AU+62$0TAXBDASQ]CER@
M2KDWM,2"'V$F+.US?'Q*PI( 07)!(+I,$P&U'P!. *0HCPU(C%1)0F"L1510
ME*B8D%,(J,:"R>DQH28D$+*(96(JT)-]9= A(OWB&TDLURQ!=APXX:/6% LY
M( ET@ N_M:FVF#,&Y&$OH2$E3)0J 9D1%'IA^ F(F&J(J.?Q?2"I,4@GK]77
M#G&,HM,55 5082&!-^T@$,&%B2+S>7$ ,IK,5,=Y=+ZG[SJ+$ M(9W"88EZJ
MH:D1C+JAQ(<RA 5$EHJ3"F825>+TF- B]$> #X40-&0@@(((!(>M5*FLC03W
M73).X#.8W>.+ $C#UU$L20=3Z0D) +$CNN> WX.64[T51$( 4I:4I8*4I:@A
M*$*VB1"HM"A*(*41(I0A:F0A16H)-1*4.Y9@)T@$,.>S.8!=[F^&BBHD%*2)
M((!*N\3Q(().[$<+@XAUPB5I\6'XB64J"8B/6 E2DP^KU?J$?PPM<-"U='3#
M5$A"(4^+#"YTZR.\Y,6N 0&BQD;EV&X<XF4UJ)TI22%*"GM)N'@$!K.YV,OB
M:4I45!)3$*$Q%J\(^*PA'I4H^&5.E2_9AD#IB[0O$< V=O3(81#."HNS19AL
M.+D-R%&LX+/I4 &TP7U7=X4RBS!@RE .P62K(()1+JZBDHZ43,!4S!C**P F
M$J GQ/%5TPX8($122N&%4JJ4RH)>%!]SN0&@&20()C:^&JC57JK%PM+H 3ID
M00[K!(F^F2>#$3(4A49*T*0N&%*5#6EHB4(6J&J(4%EF$E23^.Z3" Z5]00I
M"E6+HTT(U!W,F%. >4Q&\SSC..TJ+*5$&Q =)<[@- BX%IQ31$AQ8?B0UHC0
MP0%*@J$=(479),-QU'(2G=PV2.,W:)4ZH-Q=X?;@8FXX@2,6G+K2=*T*<'46
MTM(:1J 8 <_TQ4#"")E:50H$5*UHCQ4J@P%0X,N)A<41(H0@P_!Z>F(Y1$B*
M$&&I492(:I=HB &$;NSEW!.[2]^ WP)HJ)42DA14 !!86! 2Y=0D@L2\DB<)
M)0ZRCJB%"0J(83Q^@*44!)\+J(62RO"<Q!"*8I0(2DJ5IR!I+KJ$!0 9,M[(
M.[;0>+%G=L1S*:U*@@A) <@J*DJ]I8))9U"3=P TM<^Z'H%H01S&:O$]77]4
MQ)3LQ^D=';"L#'D^-M\<M]*R4T<O3*0/:!?8@ $@[P3SX;8ZMZ,2:^92%*)>
M&( (+F-G<L;D0XC'TZWO?%+L6!0HM3I-RU^=N6NPK;H=(MRFR57JLW5(T"/-
MHA0Q/34A(0('J\O'BDS4[!0T-2>KQ%)0?SXE8J)"Q#]X':7WMQVB[$-C]"U!
MI44[I8.S;!H<V\9QV<K==NQ%+EYJI4ND525I\2IU2@5B?H\A7Z%)0$%<U,5Z
MD2E2FD4F#(PR%SL>)&5)2J5PHD693#CPE+:50+[3)!AX+!_%A/,'$03SY>30
MS28#>0;'56WJ38=YR")^C7%1IJ#,5ZX;=I,O,5*G2L:M5"U:G4:/6YNW5*F$
M1:E3Y2?I%1@B<EDQ8"O 7T1(C J@:85+0Y(N!=V)!@D[7(&TXSE+*6Y([Q>[
MP6A)DM/A((< 8[:3O6RIQ"UR5XV=/0H$G,3L6-+W319B'"DI12D34U'CPI]4
M(08)25QEJ6@)0E4=1$))6%V8/X0/(W87)',7)8Q)&%(N0186XP=N' 7ERQQU
M2-3M,HE8F: B_K(-6D:;)UJ8EC<M)2E-*J"E(DYZ'-*G1*S,M,+!$.)+QHK
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MN6+2J'/W+4M.:Y2K;A09:$FDR$:X?G*) @2"XM*FJD8Y1$1$5]KCS>D:5:N
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MU"HSDNJD3E>N2I5&4ASGSDM<RJJQZM,J7!_$SDJE24!]O18@J5 (D,"68J4
MX+,\"+L<4E"W)879W<B; L0EX=R0>0Q:=P<ET6LR5>HL#4*GRE,NB?%:K!F+
M+3/3QJ4K2[IHDK!EEKKP0*:NG70I,Q"6GK,Q)HB@ N[]8R[AC(#>RLN2 "3
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MX)0(W_&68.\A]^2/R?;TBC-\R:#;N/WVZ?MW?]I@<!R"'(SGACIS+_ZBH_\
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MR/)Z#_=UTD_^W-#;.7_CV?<[_>_!V.89NQ4W#2?D^&:J%0%I!D, '?W<L/\
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MN0X,< TN1'[LS3CX=:GMN#<2Y*@SAY!'AN,8@&7QLV^ ,LQ_.XP1C._%Z*P
M!96PVD_J.-M\9EIU1L 0'B># D@/=W!V%\(^U]IV(8L6+%W9AOG!.V_%69-2
MH0:9 +OWRH.-K.[-PP9<*0"*I=]DDE/N4QX/YXOG3/4.N:47Y;6H]N0*;,W#
M;,Q48\C#JLL9J2"ZG2*M0HQ4D+AJ6$R-3/2DI 4OK2HA)"BD"H*51"BEU(J)
M#$L24D3N!8F&<.',8D0LUJ2P0$)J(6K5J?0E3D  *!!((#L'40X88V-//1KM
M6)&L4K4"8MK4VDUVUJC8U3D[PI4SUS-L3]MR=IQI9,W;M1MZ9E8L[394U&J1
M9)<O-S=?FJI5E5#UFKK7)YDY=0(*BGF05<S^4-)MMQ-\>A4S--5@L!R!""!
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M!;R?RR/?WP=@ M/$%R[,&!>S65,LQ!#8@9T)2H$@@D :G8@"7U  [Z0&*MP
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M#CCNSRWQQ']<)<_&!\P\O)VS]6E2?9V+W4WN[/A^_!_#M%QWD ?_ %5@D/+
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M@<O&7?\ >TJ;'!<G]U1.SE]PVX'#_AVC(UI+'_56]_\ @;P\;$V9Z:4![-4
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M?A%A&^)$)'4X5E) ZHA+>R=ST,2=N^1N-P:QL#[AMY_TP!0OOO(?WRQ>.)>
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M+[+6+IEYA^$?X<;R'M&(_K;7F#<?V1FAP&7_ &JN\@=LI^C8?L1OC?W/[8'
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M8CIG9C(#[\W! \0S#X#]18,Y<.5(W8@#<N,AV9CV(QP-']2>,_6QX8>EI@,
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MSJVX^6_B_ WY(>EC]&4&/X36F>-WC53SP6,@,'+[C'Q)#D,\(*2(MJ%N0_;
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MW ^KX1VEA#1P?XAY'$\&PO?[O+/]?=P-?D;[7;!Y-8/P@ O'+R<X?"P. =C
MN&@!M[.'M,8.'$^$>+C]'P$N7 WE[<O?N^#@V8\FF.+_ %Q.' !LUGX*$^;R
MQV!VPA[OZ_D]W Q):3_,[O:3// !/'8$[,)#3;W.!A\$A]MC^HPGEW9Q)9IC
MAS8GD>.#@V\9^>WZX1)#A]W/%^?ZW\<']=^*ZD:8?OH-I:X\'_5L.X7,:%D
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M]2*Q;M.IM'A7]"JLE.34**F"#'1"I\NN8@TZ:,0HC2\-#]9/5QD4P40+$GG
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MJJAOL3B3S]WP#\':9*9!,'^CQPM; 1F7(D-#!)L1/B7:.1\<(P)B&GQUR<W
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M,WMYRY8>?Y8_:P##L38B%29=_9W)EK<3.))Z,B*I!)22Z($"_P!X_%GAS(+
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M ):P)\O<?#?SQHSR\T:P:OJ5SE52Y+9H%;J$3FEJ,K"G*M;E*J$[#E)+1O2
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MO CXXGV--0FFD>('PY^6(?1G1T!AIW:+.-[/H'YOV&_^@\2_O7^LH^"B&O\
MUE_?8%&D W9I;P??G;$OHQI Q!T[M#+AQ:% (*<X?U,=)/3[+95EGX/[T_\
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M?/;#G]=C'.[? CD^)H2.I)9*2%)&.LD%QDA2FW\P3Y)+Y;#Q8N'V^O&/<T%
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MZ!5^P;:C2<:8D[@3IY=]1K%;EYR-U"!(I3(JEH+3 =0B*,8J[8JE-2E@@J
M5J+28C8N'XLPMS82D.27)((LT%SS?8-R=R,;YW'KAR):D\VNF'/I6.9C4BTK
M@E[ET;KEP<O:=.9F?G+8K=E3=&E:_ 3=L.LBE_5V)&27,T^3E*<F;"T+(BJZ
M@GC*:)[R'4S*93B2089@(!V-O#%W:AP3IA1!2Q+;AIDP&V<$3#T><'TB'+?J
M]:%J7!8FG&F%<AZ=ZK:S0:ERZWK:M<E=,K^.HMU0Z]2>9:FS%)J4E4Y2[*Q2
MI1%OU^DU&H1H4"8C^NR\M!2PXDBBH+E18Z \.P"0QBVIR[N7LP+I59T[#VB
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MS:+7YP+6WVP>'!?,O <C'XB"0Y41C\7_ #@Q#-Y['B3GB=MSM;Y86A$=T0"
M6XF;W!'A^ZZ8./V-+$#'\7@$[MC\6Y';L[]B_"[VHJU*FX>.5FY[XBJDA0L'
M$ @.0/,6/#A&%TA! AI3#2I1)1#0F&@.<F&E 2(<4[+C)'B$>R5$<)8*PQ49
MON2'>Y^KXOHJ%$@A"2S00P(\!,^.*C!#B&@H0P8*/6'+ ^T<X#OD[ XX$C2
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M#89UN8.U[1PY.\LSB#C'3;4EV]IP)=]1DQXMP#>)V9!!?VD@>8V!8$LY #L
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MI]KP!>8M,_!GE]\4UPX3'XP1<MW5'@]HM^^-N)Y:!'B +ZCXJR_V@D=$(*(
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M>X!F+%1"74YPYW /&*K!$BY:8,@&Y@.9!:^+J9<K+"R?/VI9^?"X@,^%XH#
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MD@FX)C< X^P)-*IZB3ZE*AR7/ADD[^_S\CAF88XX6*J](8GDT ,8M+?1;'<
M&AF&WU_5\5/FBF]Y*7][0P'^.?R>0#?%BI5_-,<;>9^,^>'@^::;_F4OW_V,
M=]_]7D<C.>'K7'>/OYO\[G??!@^:*9_F4#_H?Z^'VB_S'!@^:*9@>HRV-OQ8
M_K\?/OPBM1NHGS^N/E@<BQ; :13#O)2Y_P#@!O+;LPV\NW#[1?YC[\&("D4[
M8R$L ._AL&)5VW)!8EVP=_*L5:W/W&P^4;<>.#Z]^)?-%,&?4H&V6AC] ^&
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M$I39NK3BI27E(!K-7$E*S-7BRTK*RTS.A<Q"E)?K*#Z-:@M*:(!46TAR2]W
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ML:5@)7ZLE!UGI#/)20]()U#4U.>\KN@$/!2^Q;?;&1/1^16=0[4*8@'M" P
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M"9@>M1R'5VB0FB*A<*4-68*EJ (U*8@$AU)<@'O$.0%!\%3-=)5%DU!3"R$
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M%L/]3DY[O_!2UE_^S\IY,W]M-F\^%]K9/_4I<;I+F[MIAOB9.#U.J3[*V,@
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MO+R<>AK@R"U*DUQH46"@*/4'DNA\_1512M6G0**2RP/82!42 " SB&@@.0
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MPRF9AAMA*2$J"(BXJ"M(6I$98(,9*UNH10">B("%PRQ0I)2&J4'.LW#GQN?
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$P8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g309570g01a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g309570g01a04.jpg
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M)#1"45AS=9:7L]08&B4F-39#5E=R=+&RM,73U?_$ !T!  $%  ,!
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M9B%4"Y)V 'MQ_.<:30]?I,!I&8VJ&N]$M399Y7;57W17L/,-6SQS'+KL710
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M&OVBBK5ZP?-%D73-VV540<MU4UD5#IG*8:R""00002""+$$;$$'<$'J,3!!
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MVM)YW,3A&WE,O$S;$+!F]K7<F CN+>52"\1(N!.MC+9%ECFHI/-=69.\7%G
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MB.;%$C9A&1C5)DP9-R"(B5!JU0202*(B)4TRAXCX>/6.2223N2;D]Y.-4
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MCU[18]N-W[YDSDV3R-D&R+QA(-7#)\T<$*JW=,W:1T'+9=,P"51%=%0Z2I#
M)3D,8HAX#UQ>6*.>*2&9%DBFC>*6-P&22.12CHRG8JRDJP.Q!(QR:GGFI9X*
MJFE>"HIIHYZ>:)BDD,T+K)%+&XL5>-U5T8;JP!&XQD6Y><6=!X=Z][^&":0H
MCJ?^.Y-H4>HY3.U]LZ^)1T4XEFXE-'V^M'3(0_F40</2M$IMB0$%Q(A\^?"%
MP)F_@YXAYM-XRN525?C609O"7!CT2<Z&G>=+&+,:(J ;E7E$:U40",0GV?\
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M2.9Q4:V,X64<N!;L6"+=JB*[A55PL*:1156545/YE#F,*))-R22>I)N?J<(
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MJ4JJ1B*$*8!*[+Z'-*6:AS*CIJ^CG73-2U<,=1!(O4:XI59"0;%3:ZL RD,
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M_H+<B_T(_P#EHWJ%)ZQ%\7^QQ.I]7E^ X 5^#)_\M<CO\FQG[:)UI9MTA_\
5?V1@#+.LGX_FQKBZQ<:V%TL+'__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
